Rolle des NF-kappaB Signalweges in zellulärer Seneszenz und Therapie-Effektivität by Jing, Hua
Rolle des NF-kappaB Signalweges in 
zellulärer Seneszenz und 
Therapie-Effektivität 
 
Dissertation 
 
zur Erlangung des akademischen Grades 
 
doctor rerum naturalium 
(Dr. rer. nat.) 
 
im Fach Biologie 
eingereicht an der 
 
Mathematisch-Naturwissenschaftlichen Fakultät I 
der Humboldt-Universität zu Berlin 
 
von 
 
M. Sc. Hua Jing 
 
 
Präsident der Humboldt-Universität zu Berlin 
Prof. Dr. Jan-Hendrik Olbertz  
 
Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I 
Prof. Dr. Stefan Hecht 
 
 
 
Gutachter: 1. Prof. Dr. rer. nat. Achim Leutz 
          2. Prof. Dr. med. Clemens A. Schmitt 
          3. Prof. Dr. rer. nat. Claus Scheidereit 
 
 
 
Tag der mündlichen Prüfung: 8. Mai 2013
 Abstract  
Cellular senescence is a terminal cell-cycle arrest program that is executed in 
response to cellular stresses, such as activated oncogenes or DNA-damaging 
anti-cancer chemotherapy, where it serves as a tumor-suppressive mechanism or 
contributes to treatment outcome, respectively. Recently, transcription factor 
NF-kappaB which has long been linked to cancer development primarily through its 
oncogenic functions, has been postulated to participate in a senescence-associated 
and possibly senescence-reinforcing cytokine response, thereby suggesting a 
tumor-restraining role for NF-kappaB. 
 
The aim of my PhD project was to understand the role of the NF-kappaB pathway in 
senescence and cancer treatment outcome. In this thesis, I show markedly elevated 
NF-kappaB activity upon therapy-induced senescence (TIS), associated with strong 
upregulation of NF-kappaB-controlled cytokines. TIS is associated with and depends 
on hyper-activated NF-kappaB signaling. By characterization and genetic engineering 
of primary mouse lymphomas according to distinct NF-kappaB-related oncogenic 
networks reminiscent of diffuse large B-cell lymphoma (DLBCL) subtypes, 
Bcl2-overexpressing germinal center B-cell-like (GCB) DLBCL were identified as a 
clinically relevant subgroup with significantly superior outcome when NF-kappaB is 
hyperactive.  
 
These results demonstrate the context-dependent role of NF-kappaB signaling in 
cancer therapy and unveil oncogenic scenarios in which NF-kappaB hyperactivity 
unexpectedly accounts for superior long-term outcome to therapy. This finding has 
significant ramifications for future clinical trials that aim at inhibiting NF-kappaB 
activity based on the assumption of its detrimental impact on treatment outcome.  
 
Keywords: NF-kappaB, senescence, cancer therapy, lymphoma, mouse models, 
DLBCL 
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 Zusammenfassung  
Zelluläre Seneszenz beschreibt einen terminalen Zellzyklus-Arrest. Nach zellulärem 
Stress u. a. durch aktivierte Onkogene oder DNA-schädigende Chemotherapie wird 
Seneszenz induziert und kann so zur Tumorsuppression bzw. zum 
Behandlungserfolg beitragen. Vor kurzem wurde gezeigt, dass der 
Transkriptionsfaktor NF-kappaB – welcher bisher vor allem durch seine onkogenen 
Funktionen mit Krebs in Verbindung gebracht wurde - bei der Seneszenz-assoziierten 
Zytokinausschüttung mitwirkt und den seneszenzten Phänotyp möglicherweise sogar 
verstärkt, wodurch NF-kappaB potentiell eine tumorsuppressive Rolle zukäme. 
 
Ziel dieser Arbeit ist die Untersuchung des NF-kappaB-Signalweges in Seneszenz 
und Therapie. In der vorliegenden Arbeit zeige ich die deutliche Aktivierung von 
NF-kappaB nach Therapie-induzierter Seneszenz (therapy-induced senescence, TIS) 
und erhöhte Expression NF-kappaB-regulierter Zytokine. TIS ist vor allem in vivo mit 
starker Aktivität des NF-kappaB-Signalweges assoziiert und von selbiger abhängig. 
Primäre Eµ-myc-transgene Mauslymphome wurden nach ihrer endogenen 
NF-kappaB-Aktivität klassifiziert bzw. mit inhibierenden und aktivierenden 
NF-kappaB-Konstrukten modifiziert, welche auch in diffusen großzelligen B-Zell 
Lymphomen (diffuse large B-cell lymphoma, DLBCL) als natürlich vorkommende 
Mutationen gefunden wurden. Über einen neuartigen „Cross-Species“-Vergleich 
wurden Bcl2-hochexprimierende Keimzentrums-B-Zell-DLBCL (germinal center 
B-cell type, GCB) als klinisch relevante Gruppe identifiziert, welche nach 
NF-kappaB-Hyperaktivierung signifikant besser auf Therapie ansprach. 
 
Diese Ergebnisse zeigen eine kontextspezifische, d. h. von „onkogenen 
Netzwerken“ abhängige Rolle des NF-kappaB Signalweges unter Chemotherapie. 
Diese Information könnte für künftige klinische Studien bedeutsam sein, da sie 
Bedingungen aufzeigt, unter denen NF-kappaB als Vermittler einer erwünschten 
Therapie-induzierten Seneszenzantwort eher nicht inhibiert werden sollte. 
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Introduction 
1 Introduction 
The nuclear factor B (NF-B) transcriptionally controls a large set of target genes 
that play important roles in cell survival, inflammation and immune recognition (Bours 
et al. 2000; Karin et al. 2002; Baeuerle et al. 1994). Aggressive B-cell lymphomas, 
among other tumor entities, frequently exhibit NF-B-activating mutations, which are 
pro-oncogenic by nature, since their targeted inactivation results in selective toxicity 
to the tumor cells (Shaffer et al. 2012). Contrasting the tumor-promoting pro-survival 
and pro-inflammatory roles of NF-B signaling, recently NF-B has been postulated 
to participate in a senescence-associated and possibly senescence-reinforcing 
cytokine response, thereby suggesting a tumor-restraining role for NF-B (Acosta et 
al. 2008; Kuilman et al. 2008). This thesis focuses on the function of NF-B in cellular 
senescence and lymphoma treatment outcome. Therefore, the NF-B pathway, 
cellular senescence, the classification of diffuse large B-cell lymphoma and the 
E-myc mouse lymphoma model will be discussed in the introduction part as 
important background information. 
1.1 The NF-B signaling pathway 
Nuclear factor B (NF-B) was described for the first time in 1986 as a nuclear protein 
binding to the kappa immunoglobulin-light chain enhancer in B cells (Sen et al. 1986). 
Subsequent studies revealed that NF-B activity is induced in most cell types in 
response to a wide variety of stimuli, with major roles in cell survival, inflammation 
and differentiation. In mammalian cells, there are five NF-B family members, RelA 
(p65), RelB, c-Rel, p50/p105 (NF-B1) and p52/p100 (NF-B2). NF-B1 and NF-B2 
are synthesized as large precursors, p105 and p100, that are post-translationally 
processed to DNA-binding subunits p50 and p52, respectively. All NF-B family 
members share a highly conserved Rel homology domain (RHD) that is responsible 
for DNA binding, dimerization, and interaction with a family of inhibitory proteins 
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known as inhibitors of NF-B (IBs) (Fig. 1).  
 
 
 
Figure 1: The mammalian members of the NF-B, IB and IKK families. (A) NF-B subunits. 
NF-B transcription factors share a highly conserved amino-terminal Rel homology domain (RHD), 
which is responsible for dimerization, nuclear translocation, DNA binding, and interaction with 
inhibitory IB proteins. RelA, RelB, and c-Rel additionally possess a carboxy-terminal 
transactivation domain (TAD) that initiates transcription from NF-B-binding sites in target genes. 
The ankyrin repeats containing NF-B1 and NF-B2 precursor proteins p105 and p100 can be 
proteolytically processed to p50 and p52. (B) IB proteins. The IB proteins are characterized by 
the presence of 6 or 7 ankyrin repeats to mediate protein-protein interactions. The ankyrin repeat 
domains bind to regions containing the nuclear localization sequence of NF-B proteins and are 
important for the retention of NF-B in the cytoplasm. Phosphorylation and ubiquitination sites on 
IB proteins are indicated. (C) IKK proteins. The IKK complex contains the catalytic kinase 
subunits IKK and IKK, as well as a regulatory subunit IKK (NEMO). IKK and IKK contain the 
kinase domain, a ubiquitin-like domain (ULD) and -helical scaffold/dimerization domain (SDD). 
The catalytic subunits interact through their NEMO-binding domain (NBD) with IKK, which 
contains a coiled coil (CC) domain and a leucine zipper (LZ).   
 
NF-B family members form homo- or heterodimeric complexes, which stay in the 
Introduction 
cytoplasm of unstimulated or resting cells in association with IBs. NF-B signaling is 
generally considered to be activated through either the classical or alternative 
pathway (Bonizzi et al. 2004). In the classical (or canonical) pathway, upon 
stimulation by proinflammatory cytokines, such as the tumor necrosis factor  (TNF), 
signaling leads to the activation of the IB kinase (IKK) complex. The activated IKK 
complex, predominantly acting through IKK in an IKK-dependent manner, catalyzes 
phosphorylation of IBs (at sites equivalent to Ser32 and Ser36 of IB), followed by 
polyubiquitination and subsequent degradation by the 26S proteasome. The released 
NF-B dimers (in this pathway, most commonly the p50-RelA dimer) translocate to 
the nucleus, bind DNA and activate gene transcription. The alternative (or 
non-canonical) pathway is strictly dependent on IKK. Activated IKK phosphorylates 
p100 at two C-terminal sites. Phosphorylation of p100 leads to its ubiquitination and 
proteasomal processing to p52, creating transcriptionally competent NF-B p52/RelB 
complexes that translocate to the nucleus and induce target gene expression (Fig. 2).  
 
A wide array of stimuli, including inflammatory cytokines, bacterial and viral products, 
results in NF-B activation by the classical pathway. Beside these, NF-B also 
responds to genotoxic agents that cause damage to nuclear DNA. Whereas a 
majority of the known inducers of classical NF-B activity function exclusively by 
transducing cell surface and/or cytoplasmic signals to the cytoplasmic IKK:NEMO 
complexes, the action site of genotoxic agents is located in the nucleus. Due to the 
spatial separation between the initiating event (DNA damage in the nucleus) and the 
signal target (inactive NF-B in the cytoplasm), the concept of a 
nuclear-to-cytoplasmic NF-B signaling pathway was proposed; it is now clear that 
such signaling pathways may be induced by multiple distinct genotoxic agents, 
resulting in the activation of a cytoplasmic IKK complex, and translocation of NF-B 
into the nucleus to modulate the expression of a subset of genes. An example is a 
pathway that involves the DNA damage-responsive kinase ataxia telangiectasia 
mutated (ATM), PARP-1 and nuclear IKK (Wu et al. 2006; Stilmann et al. 2009; Hinz 
et al. 2010) (Fig.2). 
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Figure 2: Classical (canonical) and alternative (non-canonical) NF-
NF-B is activated by pro-inflammatory cytokines and DNA da
via ATM and PARP-1) and then induces inflammation-
transcription upon nuclear translocation of the p50/Rel-A NF-B
p52/RelB subunits in the alternative pathway (ada
1.2 NF-B in cancer biology 
NF-B controls gene expression by binding to
and enhancers, thereby orchestrating a plethora of biological functions, including 
apoptosis, cell adhesion, cellular stress response, inflammation and immunity. Since 
their discovery, NF-B transcription factors have been suspected to be involved in 
cancer development because of their kinship with the v-Rel oncogene product. The 
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constitutive activation of NF-B was then observed in different kinds of cancer, 
including lymphoma, leukemia, breast, colon, liver, pancreas, prostate, and ovarian 
cancers. Moreover, constitutive activation of NF-B is associated with recurrence of 
cancer, poor survival, tumor progression, aggressiveness, and chemoresistance 
(Arkan et al. 2011; Prasad et al. 2010; Basseres et al. 2006). However, the 
relationship between NF-B and cancer is not simple and cannot be reduced to one 
grand theory. There are also studies that found NF-B transcription factors or 
upstream activators rather to act as tumor suppressors 
reviewed in the following (Fig. 3). Given the context dep
the complexity of NF-B-governed biological respons
these responses by both oncogenes and chemotherapeutic agent
functions other than anti-apoptosis are likely to impa
 
 
Figure 3: Pro- and anti-cancer roles of NF-B. The double-edged impact of NF-B on cancer 
development underscoring the complexity and potential context dependency of NF-B 
network-mediated effector functions. Note that the involvement of NF-B in some biological 
responses, like cellular senescence, might be one of the explanations for NF-B’s anti-cancer 
effect.  
1.2.1 Pro-cancer roles of NF-B 
NF-B controls oncogenic functions that suppress apoptosis or that promote tumor 
growth and survival. Mutations in genes encoding NF-B subunits or IB proteins 
were identified in a variety of hematological malignancies (Neri et al. 1991; Franzoso 
(Ben-Neriah et al. 2011), as 
endency of NF-B’s functions, 
es, the inducibility of many of 
s, NF-B effector 
ct on treatment efficacy.  
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et al. 1992; Compagno et al. 2009). There are now a number of lymphoid 
malignancies known, where constitutive NF-B has been implicated as an essential 
oncogenic lesion. This was first discovered for Hodgkin’s lymphoma (Bargou et al. 
1996, 1997; Krappmann et al. 1999; Emmerich et al. 1999). Mutations of multiple 
genes, including IKK, c-Rel, A20, CARD11, Malt1-Bcl10, CD79-ITAM and Myd88, 
cause deregulation of NF-B pathway in human lymphomas (Zhou et al, 2004; Ngo et 
al, 2011; Rosenwald et al. 2001; Sun et al, 2004).  
 
Activating mutations in CARD11 (which encodes Carma-1) have been detected in 
activated B cell–like diffuse large B cell lymphoma (DLBCL, for more detail, see 2.4). 
Such mutations generate constitutively active Carma-1 that associates with the 
Bcl-10–MALT1 complex without antigenic stimulation, which results in persistent 
activation of NF-B (Ngo et al. 2006; Lenz et al. 2008a; Staudt et al. 2010). A20 a 
negative regulator of the NF-B pathway, prevents excessive activation of NF-B in 
response to a variety of external stimuli (Wertz et al. 2004; Heyninck et al. 2005), and 
is frequently inactivated by somatic mutations and/or deletions in B-cell lymphomas, 
indicating that uncontrolled signaling of NF-B caused by loss of A20 function is 
involved in the pathogenesis of subsets of B-cell lymphomas. Multiple myeloma is 
also a lymphoid malignancy associated with NF-B activation. Although no mutations 
in NF-B or IB encoding genes have been discovered in this disease, extensive 
genetic analysis of primary tumors and multiple myeloma cell lines have revealed a 
number of mutations in genes encoding upstream signaling molecules that lead to 
stabilization and accumulation of the NF-B inducing kinase (NIK) (Annunziata et al. 
2007; Keats et al. 2007).  
 
Although oncogenic mutations in NF-B signal mediators appear to be rare in solid 
tumors, oncogenic signaling may enhance NF-B activity in the absence of mutations, 
as inflammation-associated NF-B-driven cytokine production promotes 
carcinogenesis in a noncell- autonomous fashion (Staudt et al 2010; Ben et al. 2011). 
Accordingly, mouse models demonstrated an oncogenic role for NF-B in the 
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development of lymphomas and solid tumors (Basseres et al. 2010; Calado et al. 
2010; Yang et al. 2010). 
 
In addition, the number of tumors with activated nuclear NF-B is much larger than 
the subfraction of malignancies with confirmed mutations in NF-B- or IB-encoding 
genes. Such observations led to the proposal that some of the NF-B activation seen 
in cancer is due to mutations that affect components of signaling pathways that 
activate NF-B or is the result of exposure to inflammatory cytokines in the tumor 
microenvironment.  
 
Production of the cytokines by immune cells that activate the NF-B pathway in 
pre-malignant cells to induce genes that stimulate cell proliferation and survival is a 
major tumor-promoting mechanism (Grivennikov et al. 2010). For example, TNF and 
IL-1 secreted by the environmental cells were shown to act on premalignant cells 
where they activated NF-B. NF-B activation further induced expression of genes 
involved in blockade of apoptosis, promotion of proliferation and angiogenesis, 
mechanisms collectively enhancing malignant properties (Popivanova et al. 2008; Tu 
et al. 2008).  
 
The NF-B pathway also correlates with chemoresistance in cancer treatment. 
Activation of NF-B occurs in response to DNA damage, the mode by which most 
conventional chemotherapeutic agents exert their anti-cancer activity. Activated 
NF-B binds to specific DNA sequences in target genes. Among these, a number of 
NF-B target genes, including bcl-2 (Catz et al. 2001), bcl-xL (Tamatani et al. 1999), 
COX-2 (Yamamoto et al. 1995), cyclin D1 (Guttridge et al. 1999), survivin (Zhu et al. 
2001), and XIAP (Stehlik et al. 1998) mediate the process of chemoresistance and 
radioresistance in a wide variety of tumor cells. In activated B-cell-like (ABC) 
subtypes of diffuse large-B-cell lymphoma (DLBCL), downstream targets of NF-B 
are involved in apoptosis inhibition and may thereby block the action of many forms of 
chemotherapy (Baldwin et al. 2001). The constitutive activation of the NF-B pathway 
7 
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may thus contribute to the poor response of the ABC subtype to chemotherapy 
(Alizadeh et al. 2000; Rosenwald et al. 2002; Lenz et al. 2008a). Moreover, inhibiting 
NF-B activation resulted in the reversal of chemoresistance and an enhanced 
anti-tumor efficacy in a gastric cancer cell line, thereby further supporting the view 
that NF-B may indeed mediate resistance to cancer therapy (Uetsuka et al. 2003).  
1.2.2 Anti-cancer roles of NF-B 
Although NF-B transcription factors have an oncogenic role in cancer development 
and mediate chemoresistance in cancer therapy, other studies found NF-B 
transcription factors or upstream activators rather to act as tumor suppressors, 
thereby underscoring the complexity and potential context dependency of NF-B 
network-mediated effector functions.  
 
NF-B has also been shown to mediate apoptosis (Wang et al. 1998 and Ryan et al. 
2000). In contrast to NF-B’s anti-apoptosis function, RelA and c-Rel may have a 
proapoptotic function in T cells, B cells, fibroblasts, neuronal cells, and HeLa cells. 
(Kasibhatla et al. 1999; Sheehy et al. 1999; Martin et al. 2009; Schneider et al. 1999; 
Kaltschmidt et al. 2000). NF-B can also influence the apoptotic response differently 
depending on the developmental stage of immune cells. For example, overexpression 
of RelA caused cell-cycle arrest that is followed by apoptosis in the pro-B cell line 
220-8, whereas overexpression of RelA in the WEHI 231 immature B-cell line or in the 
mature B-cell line M12 did not induce apoptosis (Sheehy et al. 1999). NF-B factors 
have double edged-function even in the same cell. Constitutive expression of c-Rel at 
an early stage imposed a resistance against TNF-induced apoptosis and later 
increased the level of spontaneous apoptosis by up-regulation of the manganese 
superoxide dismutase (MnSOD) in Hela cells (Bernard et al. 2002). 
 
Furthermore, some mouse model-based studies found NF-B transcription factors or 
upstream activators to act as tumor suppressors. The first evidence directly linking 
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NF-B to tumor suppression was from experiments using murine and human 
epidermis. Functional blockade of NF-B in epidermal cells resulted in severe 
hyperplasia of the skin in transgenic mice, which could be reversed by 
overexpression of active RelA and p50 subunits of NF-B, suggesting a 
tumor-suppressive effect of NF-B (Seitz et al. 1998). In a diethylnitrosamine-induced 
hepatocellular carcinoma (HCC) mouse model, hepatocyte-specific ablation of IKK  　
strongly enhanced the development of HCC (Maeda et al. 2005). Hepatocyte-specific 
ablation of IKK or TAK1, which are both required for the activation of IKK and NF-B, 
resulted in spontaneous liver damage, hepatocyte death, liver fibrosis and 
development of HCC (Luedde et al. 2007; Inokuchi et al. 2010; Bettermann et al. 
2010). Myc oncoproteins (c-Myc, N-Myc and L-Myc) were activated in ~70% of 
human malignancies (Dang 1999; Nesbit et al. 1999). In the E-myc transgenic 
mouse model, NF-B2 loss accelerated lymphoma development by impairing Myc's 
apoptotic response, suggesting that tumor suppression function of the non-canonical 
NF-B pathway (Keller et al. 2010). 
1.3 Cellular senescence and cancer  
One mechanism that might be related to the anti-cancer function of NF-B is cellular 
senescence, which acts as a tumor suppressive mechanism to prevent the 
proliferation of seriously damaged cells. Silencing of NF-B transcription factors in 
senescent human fibroblasts enhanced their proliferative capacity, suggesting that 
NF-B signaling may contribute to the senescent growth arrest (Rovillain et al. 2011). 
NF-B also triggered a cell-cycle arrest in normal human epidermal cells. 
IB-mediated blockade of NF-B resulted in the bypass of growth arrest triggered by 
oncogenic Ras, contributed to the generation of malignant human epidermal tissue 
resembling squamous cell carcinoma (Dajee et al. 2003). Furthermore, several recent 
studies demonstrated that senescent cells secreted chemokines, which have NF-B 
binding sites in their promoter region and have cellular senescence reinforcing 
function. Chemokines such as interleukin 8 (IL-8) and other chemokine receptor 2 
9 
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(CXCR2) ligands reinforce growth arrest of senescent cells in a positive feedback 
loop through their ability to boost the DNA damaging response (DDR) (Acosta et al. 
2008). Other NF-B targeted genes encoding secreted proteins, such as IL-6 and 
PAI-1, are involved in the induction of senescence by inhibiting proliferative and 
mitogenic pathways (Kortlever et al. 2006; Kuilman et al. 2008). 
 
DNA damage induced by anti-cancer therapy (i.e. chemotherapy, radiation) is the 
common principle by which these moieties act to trigger cellular responses, including 
programmed cell death (apoptosis) and cellular senescence. Programmed cell death 
induced by DNA damage is an important mechanism of tumor suppression and 
benefic for the treatment outcome in cancer chemotherapy. In addition to apoptosis, 
therapy-induced senescence (TIS) has been identified as another drug-responsive 
program that impacts the outcome of cancer therapy (Chang et al. 1999; Schmitt et al. 
2002a). 
1.3.1 Cellular senescence 
The evolution of the cellular senescence concept 
 
Fifty years ago, Hayflick and Moorhead described cellular senescence as a terminal 
cell cycle arrest that reflects the exhaustion of the replicative potential in cultured 
human fibroblasts (Hayflick et al. 1961). Later, DNA damage signals emanating from 
eroded telomeres that progressively shorten every time the cell divides, were 
unveiled as the underlying mechanism of the irreversible block in the G1-phase of the 
cell-cycle (Harley et al. 1990). Several years later, findings demonstrated that a 
phenotype indistinguishable from replicative senescence, called premature 
senescence, can be acutely induced in normal as well as cancer cells by a variety of 
stresses, including DNA damage and oncogenic signals (Serrano et al. 1997; Jones 
et al. 2000). Unlike replicative cellular senescence, premature senescence arises 
independently of telomere shortening. In recent years, evidence for the existence of 
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premature senescence in vivo has been accumulating rapidly and points to a critical 
role in tumor suppression (Braig et al. 2005; Collado et al. 2005; Michaloglou et al. 
2005). Senescence not only stops cell proliferation but also has other functional 
implication. Over the past several years, senescent cells were found to be cleared by 
the immune system (Xue et al. 2007) and the importance of secreted factors in 
senescence was realized (Kuilman et al. 2008; Coppé et al. 2008; Wajapeyee et al. 
2008).  
 
Features of senescent cells 
 
Cellular senescence is a growth-arrest program that limits the lifespan of mammalian 
cells and prevents unlimited cell proliferation. Senescent cells are viable, remain 
metabolically active and undergo characteristic changes in morphology. They flatten 
out and display a vacuole-rich cytoplasm. Lysosomal activity of the cytoplasmic 
-galactosidase enzyme is increased in senescent cells, which can be detected by a 
colorimetric assay using X-gal as a substrate (Dimri et al. 1995). Senescent cells 
reorganize their chromatin in specific domains and accumulate 
senescence-associated heterochromatic foci (SAHFs) (Narita et al. 2003). These 
SAHF are specifically enriched in methylated Lysine 9 of histone H3 (a modification 
catalyzed by the histone methyltransferase Suv39h1). Senescent cells show an 
altered gene and protein expression pattern compared to normal cycling or quiescent 
cells (Dimri et al. 1995; Shelton et al. 1999). Upregulation of proteins like p53 
(Serrano et al. 1997; Harvey et al. 1993), ARF (Dimri et al. 2000; Kamijo et al. 1997), 
or p16INK4a are cardinal features of a senescent cell. Furthermore, cells undergoing 
senescence exhibit profound changes in their transcriptomes. A major consequence 
of this is the secretion of many dozens of factors, including cytokines and chemokines, 
termed the “senescence-associated secretory phenotype (SASP). 
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1.3.2 Pathways controlling cellular senescence 
DNA damage response 
 
Cellular senescence is, at least in part, triggered by a DNA damage response (DDR) 
initiated by increased production of reactive oxygen species and replication stress as 
a result of unscheduled S-phase entry in response to activated oncogenes or due to 
chemo-therapeutic agent (Bartkova et al. 2006; Di Micco et al. 2006; Mallette et al. 
2007). When a eukaryotic cell is exposed to stimuli like oxidative stress, oncogenic 
stress, chemotherapy or ionizing radiation, the cell mounts the orchestrated and 
conserved signaling response - DNA damage response (Ciccia et al. 2010; Reinhardt 
et al. 2009; Derheimer et al. 2010; Bakkenist et al. 2004; Jackson et al. 2009). As a 
whole, the DDR involves the detection of specific DNA damage, the activation of DNA 
damage repair mechanisms, cell cycle checkpoints, transcriptional responses and 
post-translational kinase kinases. The outcome of the DDR may consist of 
satisfactory lesion repair and cell survival, while excessive damage may result in 
persistent DNA damage, which activates the checkpoint kinases ATM/ATR and 
CHK1/2, and leads to p53 accumulation. The accumulation of p53 allows the 
activation of downstream genes such as p21, and the induction of cellular 
senescence.  
 
RB and p53 tumor suppressor pathways  
 
The retinoblastoma protein (pRb) and p53 tumor suppressor pathways represent the 
core signaling pathways involved in the induction of cellular senescence (Fig. 4) 
(Lowe et al. 2003; Narita et al. 2003 and Collado et al. 2010).  The tumor 
suppressive p53 transcription factor is required for cellular senescence. Mutation or 
deletion of the TP53 gene occurs in more than half of human cancers (Hollstein et al. 
1994). p53 accumulates in response to cellular stresses, activates a specific program 
of target genes to restrict the growth of abnormal or damaged cells by inducing 
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apoptosis or cellular senescence. The outcome reached is thought to depend on the 
type and level of stress signal involved, and the cellular context (Riley et al. 2008, 
Vousden et al. 2009). Transcriptional target genes of p53 include the 
cyclin-dependent kinase (CDK) inhibitor p21, the proapoptotic genes BAX and APAF1, 
and the E3 ubiquitin ligase MDM2 (Vousden et al. 2002, Riley et al. 2008). The 
upstream p14Arf protein (p19Arf in mice) prevents the degradation of p53 (Sherr et al. 
2006). It is not fully understood how p53 plays a role in cellular senescence, but its 
ability to transactivate the p21 promoter, leading to the accumulation of p21 protein, is 
well established as a means by which p53 can induce growth arrest (Levine et al. 
1997, Vousden et al. 2009). The p21 protein primarily acts by the inhibition of 
cyclin/CDK complexes upstream of pRb. This inhibition leads to a reduction in pRb 
phosphorylation, increased association of pRb with E2F and repression of E2F target 
genes (Fig. 4).  
 
In addition to p53, senescence is linked to the RB tumor suppressor and its signaling 
partners, including p16INK4A (a cyclin-dependent kinase inhibitor acting upstream of 
RB).The tumor suppressor activity of the pRb protein is mainly attributed to its ability 
to bind and inactivate the E2F family of transcription factors, which transactivate 
genes encoding cell cycle proteins and DNA replication factors required for cell 
growth (Bracken et al. 2004; Blais et al. 2007). In stressed cells, the transcriptionally 
upregulated 16INK4a inhibits cyclin D-dependent kinases, thereby preventing the 
phosphorylation and inactivation of the retinoblastoma protein (Collado et al. 2006) 
(Fig. 4). This promotes the repressive association between pRb and the E2F 
pro-proliferative transcriptional activators, preventing progression through the cell 
cycle, and permitting the formation of a repressive or ‘closed’ chromatin structure 
around E2F target gene promoters, known as senescence-associated 
heterochromatin foci (SAHF). In SAHF, explicitly methylation of the lysine 9 residue at 
histone H3 (H3K9) mediated the stable epigenetic silencing of E2F-responsive genes. 
Suv39h1, a heterochromatic histone methyltransferases (HMT), bound to the 
hypophosphorylated Rb protein, and, thus, was recruited into a multimeric complex 
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with E2F transcription factors. The formation of HMT/Rb/E2F complex repressed the 
expression of E2F-regulated genes (Schmitt. 2006). 
 
 
 
Figure 4: Molecular mechanisms of cellular senescence. The p53 and pRb pathways are 
central to cellular senescence control. Oncogene activation, cytotoxic drugs, telomere attrition 
and radiation have all been shown to induce the DNA damage response (DDR). DDR and 
senescence signals change the cellular phenotype through activation of the p53-p21 and 
p16-pRB pathway. NF-B pathway is activated upon DNA damage. Some studies indicated that 
p21 is a NF-B target gene (Hinata et al. 2003; Krappmann et al. 2004). Whether NF-B 
plays a positive role in cellular senescence is addressed in this thesis.   
1.3.3 Senescence-associated secretory phenotype (SASP)  
Since 1999, it has been known that the establishment of replicative senescence in 
human skin fibroblasts leads to a strong inflammatory response involving the 
transcriptional upregulation of cytokines (Shelton et al. 1999). These results were 
initially interpreted as idiosyncratic of dermal fibroblasts and the recapitulation of the 
inflammatory process associated with wound healing in vitro, a suspicion 
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strengthened by the observation that such a response was augmented by high 
concentrations of serum, since the transcriptional program of fibroblasts in response 
to serum appeared to be related to the physiology of wound repair (Iyer et al. 1999). 
We now know that senescence leads to a coordinated secretion of a large number of 
factors (Krtolica et al. 2001; Coppé et al. 2006) - the so-called 
senescence-associated secretory phenotype (SASP) – and this occurs in different 
cell types following different stresses (Kuilman et al. 2008).  
 
SASP is composed of pro-inflammatory cytokines such as IL-1, IL-1, IL-6, IL-8, 
bFGF, TGF- (in some settings), or GM-CSF, as well as inflammation-related 
chemokines such as CXCL-1/-2/-3/-5/-7, MIP-1, or MCP-1 (a.k.a. CCL2), but also 
contains secretable factors with, at least in some contexts, anti-proliferative activity 
such as IGFBPs or PAI-1, as well as factors like the MMPs that remodel the 
extracellular matrix (Acosta et al. 2008; Kortlever et al. 2006; Kuilman et al. 2009). 
Moreover, SASP is not restricted to secretable factors, but also includes cell surface 
molecules serving as ligands and receptors, for instance TNF receptors, CXCR2 or 
the IL-6R, thereby creating potential autocrine loops (e.g. CXCL-1/-5/-7 or IL-8 with 
CXCR2) (Acosta et al. 2008) or even, as claimed, intra-cellular short cuts (e.g. IL-6 
and the IL-6R) (Kuilman et al. 2008), and self-amplifying cascades (e.g. NF-B 
signaling via TNF-R).  
 
Proinflammatory cytokines secreted by senescent cells trigger a variety of cellular 
responses. In certain settings, they have pro-oncogenic effects: the proliferative rate, 
migration, and invasion of premalignant cells are enhanced when they are cocultured 
with, or grown in medium conditioned by senescent fibroblasts (Krtolica et al. 2001; 
Dilley et al. 2003; Parrinello et al. 2005). Intriguingly, in addition to influencing their 
microenvironment, some inflammatory cytokines reinforce the arrest status in a 
cell-autonomous and/or paracrine fashion by enhancing expression levels of the 
p15INK4b CDK inhibitor, and, probably, additional effector principles. For example, 
signaling through the IL-6 and IL-8 (CXCR2) receptors is essential, in a cell 
15 
Introduction 
autonomous fashion, for cells to enter senescence in response to oncogenic BRAF or 
replicative exhaustion, respectively (Acosta et al. 2008; Kuilman et al. 2008). This is 
relayed by the C/EBPand NF-B transcription factors and is associated with the 
activation of an inflammatory transcriptome.  
 
The mechanistic basis of SASP is unclear. Given the fact that many of these 
senescence-associated cytokine, chemokine and receptor genes bear NF-B- and/or 
C/EBP-binding sites in their promoters (Kuilman et al. 2008; Adams et al. 2009), a 
prediction is that the DNA damage response components NBS1, ATM and CHK2 
activate NF-B and C/EBP, which further mediate the expression of the SASP factors. 
Indeed, NF-B is a downstream target of ATM (Li et al. 2001; Stilmann et al. 2009; 
Hinz et al. 2010), although the impact of DDR factors on C/EBP is less clear. 
 
As discussed in 2.3.2, Cellular senescence is, at least in part, triggered by the DNA 
damage response (DDR). Meanwhile, the IKK/NF-B pathway, a potential key 
regulator of numerous SASP factors, is a recognized downstream target of ATM, 
which is a key component of the DDR. Therefore, it is reasonable to hypothesize that 
NF-B may be involved in the process of senescence and SASP.   
1.3.4 Cellular senescence and cancer treatment outcome 
Premature senescence is a stress-inducible fail-safe mechanism initiated via DNA 
damage response signaling evoked by oncogenic activation or anti-cancer 
chemotherapy (Schmitt et al. 2007; Kuilman et al. 2010). Moreover, cellular 
senescence is increasingly recognized as a possible outcome for the treatment 
because it can be executed by cells in response to therapeutic drugs and irradiation 
(Chang et al. 1999). Indeed, therapy-induced senescence (TIS) is detectable in 
human tumor biopsies after exposure to neoadjuvant chemotherapy (te Poele et al. 
2002) and has also been shown to improve the long-term outcome of cancer therapy 
(Schmitt et al. 2002a). 
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Therapy-induced senescence as an alternative to apoptosis 
 
Chemotherapy is still the most important treatment method for many types of cancer. 
The possible outcomes of chemotherapeutic treatments reach from apoptosis, mitotic 
catastrophe to cellular senescence. Most of the chemotherapeutic agents used in the 
clinic are assumed to exert their anti-tumor effect through the induction of apoptosis. 
However, an intact apoptotic machinery is often unavailable in malignant cells. For 
example, high expression of Bcl2, an antiapototic moiety, in lymphomas prevents 
cells from undergoing apoptosis. In tumor cells with an apoptotic defect, senescence 
could be activated as an alternative treatment response and contribute to the 
outcome (Fig.5).  
 
It is not well understood what defines the choice of a cell to respond to the treatment 
either with apoptosis or senescence. It could depend on the dosage of the 
chemotherapeutic agents with low doses inducing senescence and high doses 
apoptosis (Rebbaa et al. 2003). Moreover, the fact that anticancer therapy in vivo 
induced a rapid apoptosis response and a delayed senescence status suggest that 
the senescence machinery may act as a back-up program to substitute for or to 
reinforce an insufficient apoptotic response (Lee et al. 2003). In addition, specific 
genetic defects that have been accumulated in cancer cells during tumorigenesis are 
strong determinants of a possible treatment outcome. In tumors with apoptosis 
defects, promoting senescence may improve the treatment outcome.  
 
Therapy-induced senescence and tumor microenvironment 
 
As with many drug treatment responses, TIS may appear in a heterogeneous degree 
in tumors. In other words, not all the cells may respond with senescence to 
chemotherapeutics. As mentioned before, the expression of cytokines and secreted 
factors by senescent cancer cells may have an inhibitory effect on the growth of 
surrounding bystander cells. Alternatively, this heterogeneous response may have a 
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growth-promoting effect in some situations. Moreover, factors secreted by senescent 
cells can also act on macrophages, neutrophils, and NK cells, thereby promoting 
immune responses that, on one hand, may ultimately lead to the clearance of 
senescent tumor cells (Xue et al, 2007), but, on the other hand, might also create a 
microenvironment that fosters tumor progression (Coppé et al, 2010). Thus, the 
outcome of anticancer therapy is not only determined by a quantitative effect on 
cancer cells forced to irreversibly exit the cell cycle but may also depend on novel 
capabilities acquired by senescent cells that can impact on their malignant and 
non-malignant neighbors in different ways (Fig. 5). With further identification of 
precise pathways that regulate senescence and additional specific 
senescence-inducing agents, there will be a wider exploitation of this approach in 
cancer treatment. 
 
Figure 5: Therapy-induced senescence as an alternative to apoptosis in cancer treatment. 
In response to DNA-damaging agents, cancer cells can rapidly undergo apoptosis or may enter 
premature senescence as a potential back-up mechanism. In addition to the tumor suppressive 
function, senescence induction is accompanied by the secretion of SASP factors, which may 
further reinforce the growth arrest or induce senescence in surrounding cells. With increased 
expression of immune cell-interacting molecules, senescence cells can be cleared by immune 
cells. 
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1.4 Diffuse large B-cell lymphoma  
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disorder that shows a 
diffuse architecture, a mature B cell phenotype and large cell morphology. It is a type 
of aggressive B-cell non-Hodgkin’s lymphoma and accounts for approximately 
30-40% of all lymphomas among adults (Shaffer et al. 2002). DLBCL can be 
subdivided into subtypes based on many different criteria such as morphology, viral 
association or underlying genetic abnormalities. Clinicians have difficulties in 
choosing appropriate therapies for treating diffuse large B-cell lymphoma because 
patients present apparently similar diagnoses, but markedly different clinical 
outcomes. The heterogeneity of DLBCL in genetic features might be one reason for 
the differences in treatment outcome. With the development of the microarray 
technology for gene expression profiling (GEP), it has been demonstrated that 
different gene expression profiles indicate biologically distinct subtypes of lymphoma, 
with functional studies leading to an improved understanding of the pathogenetic 
mechanisms in lymphoma and a better classification system. 
1.4.1 Classification of diffuse large B-cell lymphoma  
According to their gene expression profiling (GEP), DLBCL can be divided into at 
least three histologically indistinguishable molecular subtypes: the activated 
B-cell-like (ABC) subtype, the germinal-center B-cell-like (GCB) subtype, and primary 
mediastinal B-cell lymphoma (PMBL) (Alizadeh et al. 2000; Rosenwald et al. 2002; 
Rosenwald et al. 2003). While PMBL is distinct from other DLBCLs, GCB and ABC 
present as the clinically most relevant subtypes. 
 
GCB and ABC subtypes apparently arise from different stages of normal B-cell 
differentiation, differ in the expression of thousands of genes and utilize distinct 
oncogenic pathways (Staudt et al. 2005). GCB and ABC subtypes also differ in their 
clinical presentation, in cure rates after chemotherapy, and in responsiveness to 
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targeted therapies (Fig 6).  
 
 
Figure 6: Gene expression profiling identified molecular subgroups of diffuse large B-cell 
lymphoma (DLBCL). GCB and ABC DLBCL differ in their presumed cell of origin, in underlying 
genetic alterations and in their clinical behavior. 
 
ABC DLBCL
 
 
 
The activated B-cell like (ABC) subtype DLBCL highly expresses genes otherwise 
found in normal activated B-cells, such as cyclin D2, FOX-p1 and NUM1/IRF-4 
(Rosenwald et al. 2003). The hallmark of ABC DLBCL is constitutive activation of the 
NF-B pathway. Analysis of the gene expression signature in the ABC-DLBCL 
subtype revealed preferential expression of a large number of classical NF-B target 
genes, including Bcl-2 family members, c-FLIP, and cyclin D2, compared with GCB 
DLBCL. Moreover, in cell line models of DLBCL, constitutive IKK activity, rapid IB 
degradation and high nuclear NF-B DNA binding activity were found in ABC-DLBCL 
but not in the GCB-DLBCL subtype (Davis et al. 2001).  
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NF-B is activated in ABC DLBCL by a variety of mechanisms including oncogenic 
mutations and a chronic active form of B-cell receptor signaling. Recent mutation 
analyses demonstrated that mutations of the NF-B pathway regulators are, at least 
partly, responsible for a substantial fraction of cases with NF-B activation in 
ABC-DLBCL. These include mutations of the coiled-coil domain of CARD11 in about 
10% of ABC DLBCL cases leading to increased oligomerization of CARD11 and 
subsequently, NF-B activation (Lenz et al. 2008). Other studies confirmed the 
presence of CARD11 mutations in DLBCL and identified additional mutations 
affecting TNFAIP3 (A20), MYD88, CD19-ITAM, C-Rel, MAP3K7 (TAK1), 
TNFRSF11A (RANK), TRAF5 and TRAF2 (Compagno et al. 2009; Honma et al. 
2009). CARD11 is a multi-domain signaling adapter that contains an amino-terminal 
CARD and coiled-coil domains, an intervening linker domain, and a C-terminal 
MAGUK domain. Prior to activation, CARD11 is located in the cytosol, where it is 
presumably kept in an inactive conformation through an intramolecular interaction 
between its coiled-coil and linker domains. PKC-dependent serine phosphorylation 
within the CARD11 linker domain is thought to relieve this intramolecular association. 
CARD11 is then able to translocate to the plasma membrane, where it binds BCL10 
and MALT1. Subsequently, MALT1 recruits TRAF6, which ubiquitinates MALT1, 
TAB2, and IKK. Ubiquitinated TAB2 activates the kinase TAK1, which can then 
phosphorylate IKK in its activation loop. Full activation of IKK requires both 
phosphorylation and ubiquitination of IKK (Shaffer et al. 2012). MYD88 is an adapter 
protein that couples TIR-containing receptors, such as the TLRs, to a variety of 
downstream signaling circuits, including the NF-B, p38MAP kinase, and type I 
interferon pathways. Another mutation found in ABC-DLBCL affects A20. A20 is a 
deubiquitinating enzyme and inactivates IKK by removing regulatory K63- linked 
polyubiquitin chains from IKK. These gene products are positive or negative 
regulators of the NF-B pathway and their alterations promote abnormal activation of 
the pathway (Fig. 7). 
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Figure 7: Mutations of regulators of the NF-B pathway in ABC DLBCL. Constitutive 
activation of the NF-B pathway promotes survival in ABC DLBCL and can be achieved by 
several oncogenic mechanisms, including mutations in CD79A/B/ITAM, CARD11, MYD88 and 
A20 (adapted from Shaffer et al. 2012). 
 
GCB DLBCL 
 
The germinal-center B-cell like (GCB) subtype DLBCL is characterized by high 
expression of the “signature” genes of normal germinal center B-cells, including CD10 
and CD38, the nuclear factor A-myb, as well as BCL-6 (Alizadeh et al. 2000; Nyman 
et al. 2007). GCB DLBCL is likely derived from rapidly proliferating centroblasts within 
the germinal center of a lymph node. In particular, the NF-B pathway is essentially 
silent in germinal center B cells, as measured by expression of NF-B target genes 
and by nuclear accumulation of NF-B heterodimers (Shaffer et al. 2006) 
 
GCB-DLBCL frequently present with a genomic translocation t(14;18) that puts Bcl2 
in the vicinity of the immunoglobulin heavy chain locus. This oncogenic event was 
found to be common in GCB DLBCL, occurring in 45% (29/65) of cases analyzed, 
and also was detected in 18% (2/11) of PMBL cases (Huang et al. 2002; Rosenwald 
et al. 2002). By contrast, BCL-2 translocation is virtually absent in ABC DLBCL. 
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Nonetheless, the majority of ABC DLBCLs express Bcl-2 mRNA at high levels, 
presumably due to transcriptional activation of Bcl-2 as an NF-B target (Rosenwald 
et al. 2002; Wright et al. 2003). 
1.4.2 NF-B and clinical outcome in diffuse large B-cell 
lymphoma 
In general, a 5-year survival rate of 60% can be achieved in DLBCL; however, 
patients with an ABC subtype have a significantly shorter survival than those with 
GCB DLBCL when treated with standard doxorubicin-based chemotherapy such as 
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), with or without 
rituximab (Rosenwald et al. 2002; Lenz et al. 2008; Wilson et al. 2008). To date, no 
therapy has shown greater benefit in ABC DLBCL.  
 
The hypothesis that the constitutively active NF-B pathway in ABC DLBCL is linked 
with inferior treatment outcome is supported by several in vitro experiments. 
Introduction of the IB super repressor to inhibit NF-B in distinct DLBCL cell lines 
resulted in rapid apoptosis and cell-cycle arrest, selectively in ABC-DLBCL cells 
(Davis et al, 2001), while the GCB DLBCL cells were not affected, indicating that the 
constitutive NF-B activity is specifically required for the survival and proliferation of 
ABC-DLBCL cells. Furthermore, the IKKinhibitors PS-1145 and MLX105 were 
selectively toxic for ABC-DLBCL cells but not for GCB DLBCL cells. Cell death was 
accompanied by decrease in the expression of NF-B target genes and an activation 
of the proapoptotic caspases 3 and 7. Introduction of an estrogen-inducible RelA 
fusion protein into ABC-DLBCL restored NF-B activity even in the presence of IKK 
inhibition. The active forms of RelA also stopped apoptosis induction by the kinase 
inhibitors PS-1145 and MLX105, demonstrating that the NF-B inhibition is directly 
responsible for tumor cell death (Lam et al. 2005).  
 
Taken together, gene expression profiling of DLBCL has revealed distinct molecular 
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subtypes that include germinal center B-cell like and activated B cell–like DLBCL. 
ABC DLBCL present with an inferior prognosis after chemotherapy and are 
characterized by constitutive activation of the NF-B pathway, which appears to 
confer treatment resistance. In vitro analyses demonstrated that inhibition of NF-B 
can sensitize ABC but not GCB DLBCL. Although NF-B’s function in GCB is not 
clear, the NF-B pathway is central to the pathogenesis of ABC DLBCL and is a 
potential treatment target in this subgroup. 
1.5 E-myc mouse lymphoma model 
Transgenic mice bearing the cellular myc oncogene coupled to the lymphoid-specific 
IgH enhancer () develop with high incidence a fatal lymphoma within a few months 
after birth. The prototype E-myc mice succumb to pre-B and B-cell lymphomas, 
following a preneoplastic phase in which cycling pre-B cells massively expanded. The 
hallmark of the disease in E-myc mice is a profound enlargement of the lymph 
nodes. The onset of tumor occurs around 3 and 18 weeks of age (Adams et al. 1885). 
 
The Eμ-myc transgenic mouse serves as a useful model to study genetic 
mechanisms of tumor development and treatment sensitivity in spontaneous B-cell 
malignancies for several reasons. Firstly, the genetics and histopathology of E-myc 
lymphomas resemble human non-Hodgkin’s lymphomas. Secondly, the tumor burden 
can be easily monitored by lymph-node palpation or blood smears. Thirdly, large 
numbers of pure tumor cells can be isolated, cultured, transduced and transplanted 
into syngeneic, non-transgenic mice. When Eμ-myc transgenic lymphoma cells were 
transplanted into normal, immunocompetent recipient mice, the recipient mice 
developed systemic lymphomas indistinguishable from the primary transgenic host 
they were initially derived from (Schmitt et al. 1999, 2000). 
 
In the E-myc mouse lymphoma model, both senescence and apoptosis were 
contributing to the in vivo response to chemotherapy (Schmitt et al. 2002b). When 
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apoptosis was blocked in E-myc lymphomas, senescence became the principal 
tumor response to chemotherapy. E-myc tumors harboring a Bcl2-mediated 
apoptotic block underwent drug-induced senescence involving the accumulation of 
p53 and p16INK4a in vivo (Schmitt et al. 2002a). Likewise, primary E-myc 
transgenic, retrovirally bcl2-infected lymphoma cells can enter senescence in 
response to the treatment of DNA-damaging drugs in vitro (therapy-induced 
senescence, “TIS”). 
 
To sum up, the NF-B pathway transcriptionally controls a large set of target genes that 
play multiple roles in cell survival, inflammation and immune recognition. In ABC-DLBCL, 
constitutively active NF-B signaling prevents apoptosis and thereby blocks the action of 
many forms of chemotherapy. In addition to apoptosis, senescence is another 
drug-responsive effector program of cancer therapy. Recent evidence points to a 
potentially tumor-suppressive function of NF-B as a mediator of the 
senescence-associated secretory phenotype. SASP, reflecting a broad array of cytokines 
and chemokines, are produced in a predominantly NF-B-dependent fashion during 
cellular senescence, presumably related to oncogene- or chemotherapy-induced DNA 
damage that is considered to initiate cellular signaling ultimately leading to the terminal, 
senescent cell-cycle arrest. Given the context dependency of NF-B’s functions and the 
complexity of NF-B-governed biological responses, NF-B’s perspective function in 
senescence are likely to impact on treatment efficacy.
Scientific aims of this PhD thesis 
2 Scientific aims of this PhD thesis 
The general objective of this PhD project is to elucidate the role of the NF-B pathway 
in senescence and cancer treatment outcome. Therefore, the following specific aims 
will be addressed: 
 Is the NF-B pathway activated in therapy-induced senescence? 
 Is therapy-induced senescence dependent on the NF-B pathway? 
 Does hyperactive NF-B contribute to treatment outcome in human lymphoma 
patients?
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3 Material and Methods 
3.1 Material 
3.1.1 Chemicals and reagents 
ABT-263 Selleck 
ABT-737 Selleck 
Adriamycin (Doxorubicin) Sigma 
Agar Roth 
Agarose Serva Electrophoresis 
Albumin Fraktion V Roth 
Ammoniumpersulfate (APS) Roth 
Ampicillin sodium salt Roth 
Bay11-7082 Sigma-Aldrich 
Blasticidin Invitrogen 
Bradford reagent (RotiQuant) Roth 
Bromophenolblue powder Eurobio 
Calciumchloride (CaCl2) Roth 
Chloroform Merck 
Dual Endogenous Enzyme Block DAKO 
Dako REAL™ Antibody Diluent DAKO 
DAPI Sigma 
Diethyl pyrocarbonate (DEPC) Sigma 
di-Sodium hydrogenphosphate dihydrate Merck 
dNTPs Roth 
DTT  Fluka 
Ethanol absolute Roth 
Ethidium bromide powder Roth 
Ethylenediaminetetraacetate (EDTA) Roth 
Fetal Calf Serum (FCS) Biochrom  
Formaldehyde  Roth 
Glacial acetic acid Merck 
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Glucose  Roth 
-D(+) Glucose (Dextrose)  Roth 
Glutaraldehyde  Roth 
Glycerin  Merck 
Glycine  Serva Electrophoresis 
HCl  Merck 
HEPES Roth 
Hexademethrinebromide (Polybrene)  Sigma 
Hygromycin B Roche 
KINK-1 provided by M. Schmidt 
Supprian (Schon et al. 2008) 
L-Glutamine  Biochrom 
Magnesiumchloride for PCR Roche Applied Biosystems 
Magnesiumchloride-hexahydrate (MgCl2) Roth 
Methanol  J.T.Baker 
Milk powder  Roth 
Mowiol 4-88 Calbiochem 
N,N,N´,N´-Tetramethylethylenediamine (TEMED) Sigma 
N,N-dimethylformamide (DMFO)  Roth 
N,N-dimethylsulfoxide (DMSO) Roth 
Na-Desoxycholate Sigma 
NH4Cl Merck 
Nonident 40 (NP-40) Merck 
Paraformaldehyde (PFA) Sigma 
PBS Dulbecco Biochrom  
PCR buffer Applied Biosystems 
Penicillin-streptomycin Biochrom  
PMSF Sigma 
Potassium ferricyanide (K3Fe(CN)6) Sigma 
Potassium ferrocyanide (K4Fe(CN)6 x 3 H2O) Sigma 
Potassiumchloride (KCl) Merck 
Potassiunacetate (KAc) Roth 
2-propanol Sigma 
Protease inhibitors (Complete protease inhibitor) Roche 
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Puromycin dihydrochloride Calbiochem 
SDS (Sodiumdodecylsulfat) Roth 
Sodiumchloride (NaCl) Merck 
Sodium desoxycholate Sigma 
Sodiumfluoride Sigma 
Sodiumhydroxide (NaOH) Roth 
Sodiumorthovanadate Sigma 
-mercaptoethanol Roth 
Taq polymerase Applied Biosystems 
TaqMan® Gene Expression Master Mix Applied Biosystems 
TNF- Sigma-Aldrich 
TPCA-1 Merck 
Tris (hydroxymethyl) aminomethane Merck 
Triton X-100 Merck 
TRIZOL reagent Gibco Invitrogen 
Trypan blue solution Sigma 
Trypsin-EDTA Biochrom 
Trypton/Pepton from casein Roth 
Tween 20 Roth 
X-Gal   Roth 
Yeast extract Roth 
3.1.2 Enzymes 
Klenow Promega 
Pfu DNA polymerase Agilent 
Proteinase K Merck 
Restriction enzymes NEB Biolabs 
RNase A Fluka 
RNasin Plus RNase Inhibitor Invitrogen 
T4 DNA ligase NEB Biolabs 
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3.1.3 Kits 
Kits Company 
Reverse Transcription Kit Invitrogen 
Dako REAL™ Detection System, Alkaline 
Phosphatase_RED, Rabbit_Mouse 
 
DAKO 
Luciferase Reporter Gene Detection Kit Sigma 
Nuclear Extract Kit  Active motif 
TransAM® NFB Family Active motif 
Immobilon Western Chemiluminescent AP 
Substrate 
 
Millipore 
3.1.4 Oligonucleotides 
Oligo Sequence 
IB forward 5’-ATAAGATCTGCCACCATGACCGAGGACGGGGACTCGT-3’
IB reverse 5’-AGCGAATTCTCATAACGTCAGACGCTGGC-3’  
Luc forward 5’-AGGAACCAGGGCGTATCTCT-3’ 
Luc reverse 5’-CGTCGCCAGTCAAGTAACAA-3’ 
3.1.5 Expression vectors for retroviral transduction 
Plasmids used in this study are ecotropic vectors based on the Moloney Murine 
Leukemia Virus (MMLV) and taken for retroviral transduction of rodent cells. The 
MSCV (Murine Stem Cell Virus) vector contains the packaging sequence (+), gene 
of interest, the PKG (Phosphoglycerate kinase) promoter and a selectable marker 
(antibiotic resistance) /or IRES-GFP between the 5´ and 3´LTR (Figure 8). For further 
details see www.clonetech.com. 
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pMSCV BSD/puro/hyg
5’ LTR
3’ LTR
+
Gene of interest
pPGK
BSD/puro/hyg
Ampr
 
 
Figure 8: MSCV BSD/puro/hyg plasmid map 
 
Vectors based on the pMSCV are listed below: 
 
Plasmid Name Backbone Insert 
MSCV-SR-BSD 
(SR = IB-ΔN) 
MSCV-BSD Part of the human IB-alpha 
cDNA (amino-acid residues 
71–317) 
MSCV-SR-IRES-GFP MSCV-IRES-GFP Part of the human IB-alpha 
cDNA (amino-acid residues 
71–317) 
MSCV-CARD11L251P-puro MSCV-puro Mouse CARD11 cDNA with 
L251P mutation 
 
pMSCV(SIN) vector 
The U3 region of the 3' LTR (sequence between restriction sites NheI and XbaI) in the 
MSCV-hyg vector was cut off. Therefore, the MSCV-SIN vector lacks the enhancer 
region of the 3' LTR, introducing the need of using an internal promoter to drive the 
expression of the reporter gene. 
 
pMSCV(SIN)-NF-B-Luc vector 
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The pMSCV(SIN)-NF-B-Luc vector was constructed based on the self-inactivating 
(SIN) MSCV vector. A fragment containing six NF-B-binding DNA consensus sites 
(GGGGACTTTCCCT) linked to a luciferase reporter gene (6×NF-B-Luc) was cloned 
into the multi cloning site of the MSCV-SIN vector to get the pMSCV(SIN)-NF-B-Luc 
vector (Figure 9). 
 
Figure 9: pMSCV(SIN)-NF-B-Luc plasmid map 
3.1.6 Bacteria strains 
E. coli DH5 Invitrogen 
 
Genotype: F-80dlcZΔM15Δ(lacZYA-argF)U169 deoR, recA1 
endA1hsdR17 rk-mk+phoA supE44-thi-1gyrA96 relA1 
3.1.7 Markers 
Marker Company 
Protein  
PageRuler™ Plus Prestained Protein Ladder Roth 
DNA  
pBR Mix 328 Roth 
GeneRuler™ 1 kb Plus DNA Ladder Thermo 
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3.1.8 Antibodies 
Antibody 
Host / 
Conjugate  
Used 
for 
Dilution Company 
Anti--tubulin (T5168)    mouse WB  1:2000 Sigma 
Anti-H3K9me3 (ab8898)  rabbit  WB 1:1000 Abcam 
Anti- IB(Sc-371) rabbit WB 1:250 Santa cruz 
Anti-Ki67 (M7249) rat ICC 1:25 DAKO 
Anti-phospho-p65 (Ser536) rabbit WB 1:1000 Cell signaling 
Anti-p65 (C-20) rabbit IF 1:250 Santa cruz 
Anti-p65 (#3034) rabbit WB 1:1000 Cell signaling 
Anti-IgG AlexaFluor 488    rabbit IF 1:400 Invitrogen 
Anti-rabbit IgG   HRP WB   1:1000 Amersham 
Anti-mouse IgG    HRP WB  1:1000 Amersham 
3.1.9 Cells 
Cell type  Medium Source 
NIH 3T3 
Adherent mouse embryonic fibroblast cell 
line, Cytogenetics: hypertriploid karyotype 
and 3% polyploidy; deleted in the Ink4Arf 
locus. 
ATCC number: CRL-1658 
 DMEM medium Cell line 
Phoenix Eco  - 
Adherent human embryonic kidney cell line 
293T, adenovirus-transformed and stably 
transfected with two plasmids encoding the 
MML virus sequences “gag”, “pol”, “env”. 
www.standford.edu/group/nolan.html 
 DMEM medium Cell line 
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MEF 
Primary mouse embrionic fibroblasts, 
isolated from E12.5 mice; adherent cells. 
 DMEM medium Primary 
B-Lymphoma cells  
Primary murine Myc-driven B-cell 
lymphoma cells isolated from the spleen or 
lymphnode of a terminally sick E-myc 
transgenic mouse; suspension cells, culture 
with feeder cell. 
 B cell medium Primary 
3.1.10 Buffers and solutions 
Solutions for Immunofluorescence Reagents 
Fixation solution 4% paraformaldehyde in 1x PBS 
prepare freshly 
Blocking solution 1% BSA in 1x PBS 
Permeabilization buffer 0.1%Triton X-100 in 1x PBS 
Detergent buffer 0.01% Tween 20 in 1x PBS 
  
Solutions for Plasmid Mini-Preparation  Reagents 
Solution I 50 mM Glucose 
25 mM Tris pH 8.0 
10 mM EDTA pH 8.0 
store at 4°C 
Solution II 0.2 N NaOH 
0.5% SDS 
prepare freshly 
Solution III 25% 5 M KAc 
15% Acetic acid 
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adjust to 100 ml with distilled water 
store at 4°C 
  
Solutions for PCR / RT-PCR Reagents 
50x TAE 242 g Tris base 
57.1 ml Glacial acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
store at RT 
DEPC water 0.1% DEPC in distilled water 
incubate at 37°C for 1 hour, autoclave
store at RT 
  
Solutions for Retroviral Transduction Reagents 
2 M CaCl2 5.88 g CaCl2  
adjust to 20 ml with distilled water 
filter (0.2 μm) 
store at -20°C 
2x HBS (Hepes buffered saline) 280 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4 x 2H2O 
12 mM dextrose 
50 mM HEPES 
adjust pH to 7.05 
adjust to 100 ml with distilled water, 
filter 
store at -20°C 
100 mM Chloroquine 0.516 g Chloroquine diphosphate 
adjust to 10 ml with distilled water 
filter (0.2 μm) 
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store at -20°C 
  
Solutions for SA--gal assay  Reagents 
PBS/MgCl2 1 mM MgCl2 in 1x PBS 
store at RT 
Fixation solution 0.25% Glutaraldehyde/ 2% 
paraformaldehyde, in PBS/MgCl2  
PH 5.5 solution 
prepare freshly 
Staining solution 9.25 ml PBS/ MgCl2 
0.5 ml 20x KC solution 
0.25 ml 40x X-Gal solution 
prepare freshly 
20x Potassium cyanide (KC) stock 20 mg K3Fe(CN)6 
1.050 mg K4Fe(CN)6x 3H2O 
in 25 ml 1x PBS 
store at 4°C in the dark 
40x X-Gal solution 40 mg X-Gal in 1 ml DMFO 
store at -20°C 
  
Solutions for Western Blot Reagents 
Protein lysis buffer (Lämmli) 1 ml of 0.5 M Tris-HCl, pH 6.8 
0.8 ml Glycerol 
1.6 ml of 10% SDS 
0.4 ml of 14.3M -mercaptoethanol 
3.8 ml distilled water  
store at RT 
SDS sample buffer 1 ml 0.5 M Tris-HCl (pH 6.8) 
0.8 ml Glycerol 
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1.6 ml 10% SDS 
0.4 ml 14.3 M -mercaptoethanol 
0.4 ml of 1% bromophenol blue 
store at -20°C 
0.5 M Tris-HCl pH 6.8 6 g Tris base 
60 ml dH2O 
adjust to pH 6.8, adjust with distilled 
water to 100 ml  
store at RT 
1.5 M Tris-HCl, pH 8.8 27.23 g Tris base 
80 ml dH2O 
adjust to pH 8.8, adjust with distilled 
water to 100 ml 
store at RT 
10x Electrode running buffer (pH 8.3) 30 g Tris base 
144 g Glycin 
10 g SDS 
adjust with distilled water to 1 L 
store at RT 
Transfer buffer 2.9 g Tris base 
14.5 g glycine 
200 ml methanol 
Adjust with distilled water to 1 L 
Store at 4°C 
25x TBS 60 g Tris base 
200 g NaCl 
9.5 ml 10 N HCl 
adjust with distilled water to 1 L 
store at RT 
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1x TBS-Tween (TBS-T) 0.2% Tween 20 in 1x TBS 
store at RT 
Blocking buffer 5% dry milk in 1x TBS-T 
prepare freshly or 
store at 4°C (1 day) 
3.1.11 Media 
Medium Component 
DMEM medium 
 
DMEM 
+ 10% FCS 
+ Penicillin-streptomycin (100 U/ml) 
store at 4°C 
B cell medium DMEM+ IMDM (1:1) 
+ 10% FCS 
+ Penicillin-streptomycin (100 U/ml) 
+ 4 mM L-Glutamine 
+ 25 μM -mercaptoethanol 
store at 4°C 
Freezing medium FCS + 10% DMSO 
store at 4°C 
LB-Medium (Luria-Bertani) 10 g Trypton 
5 g Yeast Extract 
10 g NaCl 
adjust to 1 L with distilled water (pH 
7.2-7.5) 
store at 4°C 
LB-bacteria plates 10 g Trypton 
5 g Yeast Extract 
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10 g NaCl 
15 g Agar  
adjust to 1 L with distilled water (pH 
7.2-7.5) 
store at 4°C 
3.1.12 Equipment 
Plastic-ware and other dispensable 
materials 
Company 
Cell culture dishes, sterile  
(different sizes) 
TPP 
Centrifuge tubes, sterile  
(different sizes) 
TPP 
Serological pipettes, sterile 
(different sizes) 
Falcon Becton Dickinson 
“Mr. Frosty” Freezing box  Nalgene Cryo 1°C Freezing Container
Syringes for single-use, sterile 
(different sizes) 
Braun, Omnifix, BS Plastic 
 
Neubauer cell-counter chamber (Improved 
0.025 mm, Depth 0.1mm) 
Superior Marienfeld 
 
Needles for single-use, sterile  
(different sizes) 
Neoject 
 
Disposable scalpel for single-use, sterile Feather 
Cryotubes, sterile PK-100 (1.2 ml) Simport Plastics 
Nylon Mesh (35 μm) Sefar 
Rotilabo Filter sterile (0.45 μM PVDF) Roth 
Rotilabo Filter sterile (0.22 μM PVDF)  Roth 
Microscopy Immersion Oil Merck 
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Cytospin Equipment Company 
- Centrifuge (Rotina 35R)  Hettich 
- Inserts (1670) and Plastics (1668) Hettich 
  
Western Blot Equipment Company 
Western blot chamber for SDS-PAGE C.S.B. Scientific CO 
Western blot semidry blotting apparatus 
(Transblot Semidry Transfer Cell) 
BIORAD 
PVDF membrane (Immobilon-P)  Millipore 
Whatman paper (3 MM)  Schleicher-Schuell 
ChemoCam Imager INTAS 
  
Standard Equipment  Company 
Centrifuges  Eppendorf Centrifuge 5417R 
Eppendorf Megafuge 1.0 R 
PCR machine  Mastercycler Eppendorf 
Photometer  Eppendorf BioPhotometer 8.5 mm 
Microscope Zeiss Telaval 31 
Fluorescence microscope Zeiss Axioplan 
Flow Hood Typ UVF 6.18S BDK 
Incubator  Heraeus cytoperm 2 
Real-time PCR system Applied Biosystems StepOnePlus™ 
Systems 
UV detection system Biometra T13 UV table and BioDoc 
CCD-Camera + Software 
VICTOR™ X Multilabel Plate Reader PerkinElmer 
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All instrumentation/material not listed in detail is standard lab equipment 
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Thawing of cells 
Reagents, solutions and material 
 Frozen cells in -80°C or LN2 
 Pre-warmed DMEM culture medium or B cell medium 
 Feeder cells (for lymphoma cells) in conditioned B cell medium 
Cells were thawed quickly at 37°C in a water bath and transferred dropwise to 5 ml of 
the respective medium. After centrifugation (1200 rpm, 5´, RT), supernatant was 
removeded and pellet was resuspended in 1 ml of the respective medium. Cells were 
seeded in an appropriate cell number on culture dishes or feeder cells. 
3.2.1.2 Freezing of cells 
Reagents, solutions and material 
 Cells 
 Freezing medium (4°C) 
 1x PBS 
 1x Trypsin 
 DMEM culture medium or B cell medium 
 Cryotubes 
 “Mr. Frosty” freezing box (stepwise cool down of cells; 1°C in 1´) 
Adherent cells: 
Medium was removed from the culture plate. Cells were washed with 1x PBS, 
detached with Trypsin (37°C; 1´), resuspend in fresh DMEM medium, and centrifuged 
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(1200 rpm, 5’,RT). 
 
Suspension cells: 
Cells were directly harvested from the culture plate and centrifuged (1200 rpm, 
5’,RT).  
 
After centrifugation, supernatant was removed and pellet was resuspended in 
ice-cold freezing medium. Cells were frozen in the density of 1-2x106 cells/ml freezing 
medium. Cryotubes were put into “Mr. Frosty” box and immediately transferred to 
-80°C (4h). For long-term storage, cells were transferred to LN2. 
3.2.1.3 Culture of adherent cells 
Reagents, solutions and material 
 NIH 3T3 fibroblasts, Phoenix cells or mouse embryonic fibroblast (MEF) 
 Pre-warmed DMEM culture medium 
 1x PBS 
 1x Trypsin 
NIH 3T3 fibroblasts, Phoenix cells or MEF were seeded 30-50% confluent in DMEM 
medium and cultivated under standard conditions (37°C, 5% CO2, 20% O2, 95% 
humidity) until they reached confluency. Cells were split by the following procedure: 
medium was removed and cells were washed with 1x PBS. 1 ml of Trypsin was added 
until cells detached (37°C). Cells were resuspended in culture medium and re-seeded 
in the desired density (1:2 – 1:20) onto new cell culture plates containing fresh 
medium. 
 
Mouse embryonic fibroblast were plated in DMEM medium and cultivated in low O2 
conditions (37°C, 5% CO2, 3% O2, 95% humidity). The following procedures are 
similar to the culture methods of NIH 3T3 fibroblasts or Phoenix cells. 
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3.2.1.4 Preparation of feeder cells 
Reagents, solutions and material 
 NIH 3T3 fibroblasts 
 Pre-warmed DMEM medium 
 1x PBS 
 1x Trypsin 
 Pre-warmed B cell medium 
NIH 3T3 fibroblasts were seeded in DMEM medium. When they reached 70-80% 
confluency, cells were irradiated with 20 Gy (3000 rad). 12 hours post irradiation cells 
were split according to standard procedures and resuspended in fresh B cell medium. 
Cell number and viability was assessed by trypan blue exclusion. Cells were 
re-seeded at a density of 0.5 x 105 cells per well in 6-well plates. Medium was 
changed every 2-3 days. Feeder plates were not used when feeder cells got flattened 
or vacuole rich. Medium enriched with growth promoting factors of irradiated 3T3 cells 
(12 to 24 hours after plating feeder cells) was used as “conditioned medium” for 
lymphoma cells culture. 
3.2.1.5 Culture of primary lymphoma cells 
Reagents, solutions and material 
 Freshly isolated / thawed lymphoma cells (low passage) 
 Feeder cells (irradiated NIH 3T3 feeder layer)  
 B cell medium 
Lymphoma cells were seeded at a subconfluent density (70%) on a feeder plate and 
cultivated under standard conditions (37°C, 5% CO2, 20% O2, 95% humidity). Cells 
were grown until their density reached 5 x 106 cells/ ml or medium turned too acidic. 
For splitting, about 1/3 of the cell suspension was removed (cultivated on new feeder 
plates with fresh medium, frozen or discarded). Feeder cell plates were changed after 
1 week of culture or when feeder turned too old. For this, the plate was gently rinsed 
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to remove lymphoma cells sticking on the feeders. Suspension was centrifuged at 
1200 rpm for 5´ (4°C). A few ml of the supernatant were retained to resuspend the cell 
pellet and cell suspension was subsequently transferred to a new plate of feeders 
with conditioned B-cell medium. Splitting was considered as one passage.  
 
Lymphomas cells were only used at a viability of more than 50 % and at low passages 
(to prevent selection for clones that have gained mutations by long-term culture). 
3.2.2 Animal procedures  
The main part of the animal experiments was conducted by Drs. Soyoung Lee and 
Julia Kase. 
3.2.2.1 Dissection of mice 
Reagents, solutions and material 
 Tumor-bearing mouse  
 Small box with dry ice, filled with a few ml of H2O 
 70% Ethanol 
 Mouse preparation equipment 
 Cold 1x PBS 
 4% Formaldehyde in 1x PBS 
After CO2-euthanizing the E-myc transgenic mouse at the time a well-palpable 
lymphadenopathy became detectable, animal was rinsed with ethanol and pinned 
down on a dissecting board with the belly facing up. Mouse was opened using an 
inversed “T”-cut: skin anterior to the urethral tract was held with forceps and the skin 
along the ventral midline was cut from the groin to the chin (careful not to damage the 
muscle wall underneath). Next, incision was made down near the knee on both sides 
of the animal and skin was reflected back. Transparent peritoneal wall was cut 
carefully. Body cavity was opened up and reflected back to have access to the 
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structures underneath. After removing the diaphragm on the bottom of the breast, the 
sternum was opened by lifting it up with forceps and cutting along each side up to the 
girdle to have access to the thoracic organs. Before cutting the peritoneum, 
lymphnodes that are located subcutaneously or in the connective tissue between 
muscles were checked. After opening the peritoneum, abdominal organs were 
checked for any anatomical abnormalities (right place of the organ, size and color). To 
open the sternum, diaphragm was punctured and cut along each side up through the 
cervical girdle, avoiding any damage to the thoracic organs underneath. Organs in 
the thorax were checked intensely. If at any time point organs were enlarged or 
showed abnormal features, they were cut with scissors and forceps, released from 
the connected tissue and rinsed in cold 1x PBS. After measuring the size, parts of the 
organ and the mouse body were conserved and single-cell suspensions were 
prepared for cell culture assays. 
3.2.2.2 Preparation of lymphoma cells 
Reagents, solutions and material 
 Freshly prepared organs of the respective mouse 
 Mouse preparation equipment 
 Cold 1x PBS 
 Sterile frosted glass slides 
 Sterile nylon mesh (35 μm) 
 ACK red blood cells lysis buffer 
 25 gauge needle and syringe 
 Anticoagulant (7.5 % K3-EDTA) 
Lymph nodes were washed, placed into cold 1x PBS and gently minced between two 
glass slides using the frosted side of the slides. Mixture was resuspended by 
repeated pipetting. To obtain a single-cell suspension, mixture was filtered through a 
sterile membrane and centrifuged at 1200 rpm for 5´ (RT). To get rid of red blood cells, 
pellet was resuspended in 3 ml of ACK lysis buffer and incubated at RT for 5´. Before 
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centrifugation (1200 rpm, 5´, RT), 27 ml of B cell medium were added for 
neutralization. Procedure was repeated if red blood cells remained. Cells were frozen 
or immediately used for further experiments. 
 
Importantly, primary E-myc lymphomas used for drug assays in this study were 
checked for a proper p53 pathway response (i.e. induction of total p53, 
phospho-p53-Ser18 and p21cip1) after -irradiation (4Gy) in vitro (after 4 hours). Only 
p53-pathway-intact lymphomas were included in experience +/- the SR moiety. 
3.2.2.3 Lymphoma transplantation and in vivo treatment 
 Lymphoma cells 
 PBS 
 Syringe 
 Needle* 
 Mouse restrainer 
 Cyclophosphamide (CTX) 
 
Lymphoma cells were isolated, retrovirally infected and transplanted by tail vein 
injection into normal, immunocompetent recipient mice, where they formed systemic 
lymphomas indistinguishable from the primary transgenic host they were initially 
derived from. At the moment lymph nodes became palpable in recipient animals, mice 
were exposed to a single intraperitoneal dose of the DNA-damaging anti-cancer 
agent cyclophosphamide (CTX)  (300 mg/kg body weight), and responses were 
monitored by lymph node palpation or in lymphoma material isolated at day 5 after 
therapy. 
3.2.3 Molecular biology 
3.2.3.1 Polymerase chain reaction 
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Reagents, solutions and material 
 Genomic DNA, plasmid or cDNA (100-500 ng/μl) 
 10x PCR buffer incl 15 mM MgCl2  
 dNTP mix (10 mM each) 
 Respective primer (stock 10 pM) 
 Taq Polymerase (5 U/μl) 
 dH2O 
 
A PCR reaction mixture was prepared according to the following protocols: 
 
Component Amount 
Template DNA 1 μl (5-500 ng/μl) 
10x PCR buffer with MgCl2 2 μl 
dNTP mix 1 μl 
Primer forward 1 μl (10 pM) 
Primer reverse 1 μl (10 pM) 
Taq Polymerase 1 μl 
dH2O Add 13 μl of dH2O to the total volume of 20 μl.
 
The following cycling conditions were used for PCR product amplification: 
Steps Temperature  Time 
1 Denaturation 95°C  5 min 
2 Denaturation 95°C  30 sec 
3 Annealing According to the annealing 
temperature of specific primers 
 30 sec 
4 Elongation 72°C  1 min / 1kb product 
repeat steps 2-4 34 x    
5 Elongation 72°C  7 min 
6 Hold 4°C  ∞ 
3.2.3.2 Agarose gel electrophoresis 
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Reagents, solutions and material 
 DNA in 6x DNA loading buffer 
 1 kb ladder or pBR marker 
 Agarose 
 1x TAE 
 1% Ethidium bromide 
 Equipment for gel electrophoresis 
Agarose gels were prepared according to the following procedure: agarose was 
dissolved in 1x TAE at the desired concentration and melted in a microwave until the 
solution became clear. When the solution cooled to about 50-55°C, ethidium 
brodmide was added in the appropriate concentration. After casting the gel, 
hardening occurred within 10-15´. Gel chamber was filled with 1x TAE. The aliquots 
of the DNA samples including the corresponding amount of loading buffer were 
loaded into separate wells in the gel. To determine DNA length of the fragments, an 
appropriate DNA ladder standard was used. Depending on the size of the supposed 
bands, gel was run 30-60´ (120V). DNA was visualized by UV-light. 
3.2.3.3 Preparation of RNA 
Reagents, solutions and material 
 Cells  
 TRIZOL reagent 
 Chloroform 
 Isopropanol 
 75% Ethanol 
 DEPC H2O 
 Photometer 
Cells were harvested and centrifuged at 1200 rpm for 5´ (RT). Medium was removed 
and pellet was resuspended by gently pipetting in 1 ml of TRIZOL reagent. 
Suspension was homogenized by shaking moderately for several seconds. After 
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incubation (2´-3´ at RT), 200 μl of chloroform were added to separate RNA from 
proteins and DNA. Suspension was vortexed for 15´´ and incubated for additional 
2´-3´ at RT. After centrifugation, (12 000 g for 10´, 4°C), the colorless aqueous phase 
was transferred to a new effendorf tube. To precipitate RNA, 500 μl of isopropanol 
were added to the samples, incubated for 10´ at RT and centrifuged again at 12 000 g 
for 10´ (4°C). Supernatant was removed and pellet was washed with 1 ml of 75% 
Ethanol. After centrifugation at 7500 g for 5´ (4°C), supernatant was removed and 
pellet was dried in air until ethanol was evaporated. RNA was re-dissolved in DEPC 
H2O and incubated for 10´ at 55°C before measuring RNA in a photometer 
(260/280nm) using DEPC H2O as a reference. RNA is pure at a 260/280 ratio of ≤ 1.8. 
In general, RNA was stored at -20°C and for long-term storage at -80°C. All buffers, 
solutions, tips and other equipment were RNase free.  
3.2.3.4 First strand cDNA synthesis  
Reagents, solutions and material 
 Extracted RNA  
 Oligo (dT) primer (500 ng/μl) 
 DEPC dH2O 
 5x first strand buffer 
 0.1 M DTT 
 dNTP mix (10 mM each) 
 1 U RNasin enzyme 
 200 U SuperScript Reverse Transcriptase 
1μg of RNA, 1μl dNTP mix and 1μl of Oligo (dT) primer were mixed and adjusted with 
dH2O to 13μl. Samples were incubated for 5´ at 65°C to destroy RNA secondary 
structures and incubate on ice for at least 1´. The following mix was prepared for each 
sample: 4μl first strand buffer, each 1μl DTT, dNTPs and RNasin. Mix was incubated 
for 60´ at 50°C. Reaction was inactivated by hearting at 70°C (15´). The cDNA 
product was stored at -20°C and for long-term storage at -80°C. 
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3.2.3.5 Real-time PCR 
Reagents, solutions and material 
 cDNA product 
 TaqMan® Gene Expression primers 
 TaqMan® Gene Expression Master Mix 
 dH2O 
The RQ-PCR reaction mixture was prepared according to the following protocols: 
 
Component Amount 
cDNA 2 μl (50 ng/μl) 
TaqMan® Gene Expression Master Mix 5 μl 
TaqMan® Gene Expression primers 1 μl 
dH2O 2.5 μl 
 
RQ-PCR was carried out on the StepOnePlus™ Real-Time PCR Systems (Applied 
Biosystems). Primers were ordered as TaqMan® Gene Expression Assays from 
Applied Biosystems. Real-time PCR amplification reactions were performed using the 
TaqMan® Gene Expression Master Mix. Thermal cycling conditions were as follows:  
 
Steps Temputer Time 
1 Anealing 50°C 2 min 
2 Denaturing 95°C 10 min 
3 Denaturing 95°C 15 sec 
4 Extention 60°C 1 min 
repeat steps 3-4 40 x   
 
Data were collected and analyzed with the Sequence Detection System 1.2 or 2.2 
software (Applied Biosystems). For every given sample, ΔCt values were determined 
as the difference between the Ct value of a specific transcript and the Ct value of 
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GAPDH, serving as the housekeeping control mRNA, and relative transcript levels 
(e.g., treated vs. untreated) were then produced based on 2{-ΔΔCt} with ΔΔCt = 
ΔCttreated - ΔCtuntreated. 
3.2.4 Protein biochemistry 
3.2.4.1 Western Blot 
Western Blotting was performed using a 10% or 12% SDS-PAGE-system and a 
semi-dry blotting technique. 
 
Reagents, solutions and material 
 Cell pellets for protein lysis (freshly prepared or frozen) 
 Protein lysis buffer (Triton X-100) 
 Protease inhibitors 
 Rotimark Bradford Reagent 
 BSA (stock 1 μg/μl in dH2O) 
 Tris-HCl pH 6.8 and pH 8.0 
 30% Acrylamide 
 10% SDS 
 TEMED and 10% APS 
 dH2O 
 Isopropanol 
 Sample buffer (SDS reducing buffer) 
 10x electrode running buffer 
 Western Blot equipment 
 Low or high molecular weight standards (Roti Prestained Marker) 
 PVDF-membrane (Immobilon-P) 
 Methanol 
 Whatman paper 
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 Transfer buffer 
 Semi-dry blotting apparatus 
 1x TBS-T (TBS-Tween 20) 
 5 % non-fat milk (in 1x TBS-T) 
 Washing buffer 
 First and corresponding secondary antibody  
 Immobilon Western Chemiluminescent AP Substrate 
 
Protein extraction from cultured cells  
Cells were washed once in 1x PBS and centrifuged at 1200 rpm for 5´ (RT). Cell 
pellet was resuspended in ice-cold protein lysis buffer (Volume = 3x volume of cell 
pellet) and incubated in a shaker at 4°C for 60´. To remove cell debris, lysates were 
centrifuged (14000 rpm, 10´, 4°C) and supernatant containing the proteins was 
transferred to a new tube. Protein concentration was determined by a standard 
Bradford assay and lysates were kept at -20°C or -80°C for long term storage. 
 
Protein measurement (Bradford´s protein micro assay) 
A ready-to-use Bradford solution was prepared by diluting 1 volume of 5x Bradford 
reagent with 4 volumes dH2O. A BSA standard curve was set up using 0, 1, 2, 4, 6, 8 
and 10 μg BSA including 1 μl of the protein lysis buffer each (corresponding to the 
volume of the protein lysate that is measured afterwards). To create a standard curve, 
the absorbance of the individual standard solutions was determined in a photometer 
at a wavelength of 595 nm against the no BSA-control. The curve was depicted in a 
linear regression (R2 values close to 1.0). For the individual protein lysates, each 1 μl 
was pipetted into 1 ml of the prediluted Bradford solution. The protein concentration 
was determined by the standard curve. To improve accuracy each sample was 
measured in triplicates.  
 
Preparation of the protein samples 
Protein samples were thawed on ice. Volume for the desired protein amount was 
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calculated and the respective volume of loading buffer was added to the samples. 
The mixtures were then boiled for 5´ at 95°C. 
 
Preparation of SDS-PAGE gel 
Gel plates were cleaned with 70% Ethanol and wipe clean with sterile Kimwipe before 
they were set in the casting apparatus. Separating gels (10ml) was set up mixing the 
following solutions: 
 
Compount 10 % SDS-PAGE 12% SDS-PAGE 
Distilled water 4 ml 3.3 ml 
30% Acrylamide mix 3.3 ml 4.0 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 
10% SDS 0.1 ml 0.1 ml 
 
100 μl APS and 4 μl TEMED were added to the gel mixture, vortexed and promptly 
casted between the spacers of the prepared glass plates from side to side. To 
prevent evaporation, a small layer of isopropanol was carefully added on top. Once 
the gel has polymerized (about 10-15 min´), isopropanol was removed from the 
separating gel and rinsed with water. The excess water was carefully blotted off with 
a filter paper. Meanwhile, a stacking gel was prepared (5 ml): 
 
Compount Stacking gel 
Distilled water 3.4 ml 
30% Acrylamide mix 0.83ml 
1.5 M Tris pH 6.8 0.63 ml 
20% SDS 0.05 ml 
 
50 μl APS and 5 μl TEMED were added to the stacking gel mixture, vortexed and 
pipetted on top of the separating gel. A comb with the desired number of slots was 
inserted. Once the gel has polymerized, the comb was slowly removed under running 
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water. 
 
Gel electrophoresis (SDS-PAGE) 
Chambers were filled with 1x electrode running buffer. Protein samples were loaded 
into the slots. A lane with 8 μl of a molecular weight standard (Rotimark Prestained) 
as a marker was inculeded. Gel was started at a constant voltage of 70-90 V until the 
blue dye front reached the front of the separating gel. Gel was run at a voltage of 
120-180 V until the blue dye front has nearly run out of the gel. After disassembling 
the gel apparatus, stacking gel was carefully removed. Separating gel was rinsed in 
dH2O and equilibrated in transfer buffer. 
 
Semi-dry blotting procedure 
Six pieces of Whatman paper and an Immobilon blot membrane were cut in the size 
of the gel and semi-dry blotting chamber was cleaned. Membrane was activated with 
methanol for a few seconds, rinsed with dH2O and soaked in transfer buffer. 
Whatman paper was soaked in transfer buffer. A semidry blotting “sandwich” was set 
up in the following order onto the anode platform: 
• 3 Whatman papers  
• Activated Immobilon blot membrane 
• Gel 
• 3 Whatman papers  
Air bubbles were rolled out and sandwich was blotted for 60´ at 1.2 mA per cm2 gel. 
Afterwards, blotting apparatus was disassembled and membrane was used for further 
immnmoblot. 
 
Antibody incubation 
Membrane was blocked for 60´ at RT in freshly prepared blocking solution with 
constant agitation. Meanwhile, the first antibody was diluted to an appropriate 
concentration in blocking solution. Membrane was incubated 1 hours at room 
temperature or overnight at 4°C with gentle agitation. Afterwards, antibody solution 
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was saved (and reused when stored at -20°C) and membrane was washed 3x 10´ in 
washing buffer. Subsequently, the membrane was incubated with the corresponding 
secondary antibody (RT) for 60´ under gentle agitation followed by three washing 
steps (3x 10´). Next, the two Immobilon Western Chemiluminescent AP Substrates 
were mixed 1:1 and transferred onto the protein-covered side of the wet membrane. 
After 1-2´ incubation, membrane was imaged using the INTAS ChemoCam Imager.  
3.2.4.2 Immunofluorescence 
Reagents, solutions and material 
 Cells 
 Cytospin equipment 
 Freshly prepared fixation solution (4% paraformaldehyde) 
 0.1% Triton X-100/PBS 
 PBS 
 Blocking solution (1% BSA in PBS) 
 Primary antibodies and respective secondary antibody (in blocking solution) 
 DAPI 
 Mowiol 4-88 
 
For lymphoma cells: 
Cells were harvested at the appropriate time point. After centrifugation (1200 rpm, 5´, 
RT), cells were washed in 1x PBS. Cell number and viability were assessed by trypan 
blue exclusion. 100,000 cells were transferred to a slot of the cytospin plastic and 
centrifuged at 700 rpm for 8´ (4°C). Supernatant was carefully removed by aspiration.  
 
For mouse embryonic fibroblasts: 
24 hours before harvest, cells were detached with trypsin, resuspended in culture 
medium, and re-seeded in 12-well plates with glass cover slips on the bottom. Cells 
were cultivated in low O2 conditions (37°C, 5% CO2, 3% O2, 95% humidity). Before 
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harvest, medium was removed from the plates and cells were washed in 1x PBS.  
 
Afterwards, lymphoma cells or MEF were fixed by a freshly prepared fixation solution. 
After incubation (15´, RT), slides were washed three times in 1x PBS and then 
permeabilized in 0.1% Triton X-100/PBS for 10´ (RT). After the incubation in the first 
antibody over night (4°C), cells were incubated with 0.01% Tween 20 as detergent 
buffer. Slides were washed in PBS (3x 5´) and subsequently incubated with the 
corresponding secondary antibody for 60´ (RT). After extensive washing in PBS (3x 
5´), slides were stained with DAPI as a nuclear counterstain, mounted with Mowiol 
4-88 and fluorescence was detected under the microscope. Slides were stored in the 
dark at 4°C. 
3.2.4.3 Immunohistochemistry 
Reagents, solutions and material 
 Cells or tissue cryosections 
 Cytospin equipment 
 Freshly prepared fixation solution (2% paraformaldehyde) 
 0.1% Triton X-100/PBS 
 PBS 
 Dako REAL™ Antibody Diluent 
 Dako REAL™ Detection System, Alkaline Phosphatase_RED, Rabbit_Mouse  
 DAKO Dual Endogenous Enzyme Block 
 Ki67 antibodies   
 Mowiol 4-88 
 
Cytospin preparations or tissue cryosections were fixed with 2% paraformaldehyde, 
washed with 1x PBS and permeabilized in 0.1% Triton X-100/PBS for 10´ (RT). After 
another PBS washing cycle, slides were incubated with the primary antibody against 
Ki67 (1:25; M7249, Dako, diluted in Dako REAL™ Antibody Diluent), followed by a 
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streptavidin - biotin complex peroxidase kit (Dako REAL™ Detection System, Alkaline 
Phosphatase_RED, Rabbit_Mouse), used according to the manufacturer’s 
instructions. 
3.2.5 Luciferase assay 
Reagents, solutions and material 
 Lymphoma cells 
 PBS 
 Luciferase Reporter Gene Detection Kit 
Lymphoma cells were washed once in 1x PBS and centrifuged at 1200 rpm for 5´ 
(RT). Cell pellet was resuspended in 50-100 μl of 1x Cell Culture Lysis Reagent, 
incubated at room temperature for 10 minutes and centrifuged at 12000´ g for 1 
minute (4 °C). The supernatant was removed to a new tube and stored on ice. 5 μl of 
the cell lysate was added to 25 μl of the luciferase substrate. After a fully mixing, the 
light emission was read in the VICTOR™ X Multilabel Plate Reader. Protein 
concentration was mensured by BioRad assay and used to normalize luciferase 
values (calculate RLU/μg protein by dividing luminometer reading by protein 
concentration). 
3.2.6 Measurement of NF-B DNA binding activity 
 Lymphoma cells 
 PBS 
 Nuclear Extract Kit 
 TransAM® NFB Family Kit 
Lymphoma cells were harvested and washed once in ice-cold PBS/Phosphatase 
Inhibitors. Nuclear protein was extracted using Nuclear Extract Kit according to the 
manufacturer’s instructions and stored at –80°C. Nuclear extracts were assayed at 5 
µg/ well to determine DNA binding activity of NF-B p65, p50, c-Rel, Rel-B or p52 
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subunits using TransAM NF-B p65 kit (Active Motif). Absorbance was read at 450 
nm in the VICTOR™ X Multilabel Plate Reader. 
3.2.7 Retroviral transduction 
Reagents, solutions and material 
 Low passage Phoenix cells (<20) 
 Low passage lymphoma cells or mouse embryonic fibroblasts 
 Retroviral plasmid DNA (including an appropriate marker) 
 Ecotropic helper plasmid DNA 
 dH2O 
 2M CaCl2 
 2x HBS pH 7.05 
 Chloroquine (stock 100 mM) 
 1x PBS 
 Polybrene (stock 4 mg/ml), an transduction enhancer 
 Conditioned B cell medium (filtered to prevent contamination with feeder cells) or 
DMEM medium 
 FACS equipment, puromycin (stock 300 μg/ml, final 2.5 μg/ml), Blasticidin (stock 
10 mg/ml, final 10 μg/ml-20 μg/ml)) or hygromycin (stock 50 mg/ml, final 50 μg/ml) 
Transfection of Phoenix cells 
Low passage Phoenix cells were grown in a 10 cm plate to a maximal density of 70%. 
20μg retroviral plasmid DNA, 15μg helper plasmid DNA and 62.5μl CaCl2 were mixed 
in a FACS tube and adjusted with sterile water to 500μl. After adding 500μl 2x HBS 
dropwise under constant agitation (air bubbles), DNA precipitation occurred within 5´ 
at RT. Meanwhile, old medium of Phoenix cells was exchanged for 9 ml DMEM 
medium containing 25 mΜ Chloroquine. Subsequently, the precipitate (1 ml) was 
added dropwise. Cells were cultured under the standard conditions (37°C, 5% CO2, 
20% O2, 95% humidity). 12 hours after transfection, medium including the precipitate 
was removed from the Phoenix cells. Cells were washed carefully with 1x PBS and 4 
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ml of conditioned B cell medium (for lymphomas) or DMEM medium (for MEF) were 
added to collect the first virus supernatant in 24 hours. 
 
Retroviral transduction procedure 
For lymphoma cells: 
The first virus supernatant was harvested after 24 hours by aspiration and filtered 
through a 0.45 μm filter. A well growing cell population was pelleted by centrifugation 
(1200 rpm, 5´, RT) and resuspended in the virus supernatant including 4 μg/ml 
polybrene. New medium (4 ml) was added to the Phoenix cells for the next round of 
transduction. Afterwards, cells were incubated and grown under standard conditions. 
 
After 8-12 hours of incubation, the second virus supernatant was harvested and 
added according to the procedure above, supplemented with polybrene was added to 
the lymphoma culture. After spinoculation of the plates (1500 rpm, 10´, 32°), cells 
were incubated and grown until the next round of transduction. In addition, new 
medium (4 ml) was added to the Phoenix cells for the next round of transduction. The 
third and fourth virus supernatants were collected 12 hours and 24 hours later 
according to the procedure above. 
 
12 hours after the last transduction, medium was removed from the cells by 
centrifugation and cell pellet was resuspended in fresh conditioned B cell medium. 
Lymphomas were grown for an additional 24 hours to allow cells to express the gene 
of interest. For cells transduced with GFP-plasmids, percentage of positive cells was 
determined by flow cytometry (FACS) using a non-transduced control. For cells 
transduced with an antibiotic marker, cell population was selected with puromycin (3 
day), blasticidin (5 day) or hygromycin (5 day) until non-transduced cells were 
completely dead. 
For mouse embryonic fibroblasts: 
MEF were seeded at subconfluent density 12 hours after Phoenix cells transfection. 
The first virus supernatant was harvested 24 hours after transfection by aspiration 
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and filtered through a 0.45 μm filter. Medium was removed from the MEF and virus 
supernatant including 4 μg/ml polybrene was added. New medium (4 ml) was added 
to the Phoenix cells for the next round of transduction. Afterwards, cells were 
incubated and grown under standard conditions. 
 
After 12 hours of incubation, the second virus supernatant was harvested according 
to the procedure above, supplemented with polybrene and added to the MEF culture. 
After spinoculation of the plates (1500 rpm, 10´, 32°C), cells were incubated and 
grown until the next round of transduction. In addition, new medium (4 ml) was added 
to the Phoenix cells for the next round of transduction. The third and fourth virus 
supernatants were collected 12 hours and 24 hours later according to the procedure 
of the first two rounds transduction. 
 
12 hours after the last transduction, medium was removed from the cells and fresh 
DMEM medium was added to the MEF. MEF were grown for approximately 24 hours 
to allow cells to express the gene of interest. Cell population was selected with 
puromycin (3 day) or blasticidin (5 day) until non-transduced cells were completely 
dead. 
3.2.8 Cell viability assays, apoptosis and senescence 
3.2.8.1 Assessment of cell number and cellular viability  
Reagents, solutions and material 
 All cell types 
 Trypan blue solution (diluted in 1x PBS) 
 Neubauer counting chamber 
Cells were harvested, centrifuged (1200 rpm, 5´, RT) and resuspended in an 
appropriate volume of 1x PBS. A 1:1 mixture of the cell suspension and the trypan 
blue solution was made and incubated for 1´. Cell suspension was applied to the 
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edge of the Neubauer chamber and checked for equal distribution of the cells in all 
four big quadrants. Non-viable cells were blue, viable cells were unstained. If more 
samples were counted, the trypan blue solution was added shortly before counting 
and cells were placed on ice.  
 
For viability assessment and cytotoxicity assays, at least 200 cells were counted in 
total (dead and alive). Percentage of viability was indicated as the ratio of living cells 
to the whole cell number. For total cell number and growth analysis, all viable cells in 
16 quadrants of the big 4-square-field were counted and number of living cells in 
culture was assessed by the following calculation: cell number / ml = total number of 
cells alive in 16 quadrants x dilution factor x 104. 
3.2.8.2 In vitro drug assays 
Reagents, solutions and material 
 Low passage lymphoma cells 
 Conditioned B cell medium 
 Adriamycin ADR (= Doxorubicin) 
 ABT-263 
 ABT-737 
 Trypan blue solution (diluted in 1x PBS) 
 Neubauer counting chamber 
A well growing lymphoma cells population was harvested and a small aliquot was 
taken to check viability. 1 x 105 lymphoma cells were seeded in duplicates onto a 
24-well plate with feeder cells. The following adriamycin concentrations were used: 
0.005 μl/ml, 0.05 μl/ml, 0.5 μl/ml. Cells were incubated with/without indicated 
concentration of ADR for 24 hours under standard culture conditions. In the inhibitors 
treatment setting, lymphoma cells were pre-exposed for 30 min to the Bcl-2 inhibitors 
prior to the subsequent ADR treatment. After centrifugation (1200 rpm, 5´, RT), cell 
viability was assessed using trypan blue exclusion. 
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3.2.8.3 Chemotherapy-induced senescence 
Reagents, solutions and material 
 Low passage Bcl-2-overexpressing lymphoma cells or MEF (myc - bcl2) 
 B-cell medium or DMEM medium 
 Adriamycin (ADR, Doxorubicin) 
 Various NF-B inhibitors (Bay11-7082, TPCA-1 and KINK-1) 
 1x PBS 
 1x Trypsin 
For lymphoma cells: 
Lymphoma cells retrovirally transduced with Bcl2 were harvested and a small aliquot 
was taken to check cell concentration. 1 x 106 – 2 x 106 lymphoma cells were seeded 
onto a 6-well plate with feeder cells. Adriamycin was added to the final concentration 
of 0.05 μl/ml. After 3 days of culture, the plate was gently rinsed to remove lymphoma 
cells sticking to the feeder cells and the suspension was centrifuged at 1200 rpm for 
5´ (4°C). Cells were resuspended in 4 ml fresh B-cell medium without ADR and 
seeded in another 6-well plate with new feeder cells. After another 2 days of culture, 
treated lymphoma cells were tested for their senescent status and used for future 
experiment.  
 
In the inhibitors treatment setting, lymphoma cells were pre-exposed for 30´ to the 
indicated inhibitors prior to a subsequent ADR treatment. At day 3, fresh inhibitors 
were added again into the medium. 
 
For MEF (myc - bcl2): 
MEF retrovirally transduced with Bcl2 and myc were seeded at subconfluent density 
(7.5 × 105 ) in 10 cm plate and incubated for 12 hours until all the cells were attached 
to the plate. Adriamycin was added to the medium to the final concentration of 0.05 
μl/ml. Medium was changed every three days over the experimental period. Fresh 
adriamycin was added when the medium was changed. Cells were harvested at 
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different time points for further experiments.  
3.2.8.4 Radiation-induced senescence 
Reagents, solutions and material 
 Low passage mouse embryonic fibroblasts 
 DMEM medium 
 1x PBS 
 1x Trypsin 
Mouse embryonic fibroblasts were seeded in DMEM culture medium and grown for 
12-24 hours. When they reached 60-70% confluency, cells were irradiated with 15 Gy 
-ray and cultivated in low O2 conditions. Medium was changed every 3 days and 
cells were harvest at different time points for further experiments. 
3.2.8.5 Growth curve analysis 
Reagents, solutions and material 
 Low passage lymphoma cells  
 Conditioned B cell medium 
 Trypan blue solution (diluted in 1x PBS) 
 Neubauer counting chamber 
A small aliquot of lymphoma cells was taken to check cell viability and concentration. 
Equal amounts of lymphoma cells (1x 104) were seeded in well-conditioned B cell 
medium onto a 24-well plate. Cell growth is determined over a defined period and 
viable cell number was estimated by trypan blue exclusion. To set equal conditions, 
the same feeder cells and the same conditioned medium were used. Cells were split 
onto a bigger plate when necessary. 
3.2.8.6 SA--galactosidase assay 
Reagents, solutions and material 
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 Senescent lymphoma cells or senescent mouse embryonic fibroblasts and their 
corresponding controls  
 Cytospin equipment 
 PBS with 1 mM MgCl2 (pH 5.5) 
 Freshly prepared fixation solution 
 Staining solution 
 DAPI (1 mg/ml stock solution, final 1 μg/ml) 
 Mowiol 4-88 
For lymphoma cells: 
Cells were harvested at the indicated time point. After centrifugation (1200 rpm, 5´, 
RT), cells were washed in 1x PBS. Cell number and viability were assessed by trypan 
blue exclusion. 100,000 cells were transferred to a slot of the cytospin plastic and 
centrifuged at 700 rpm for 8´ (4°C). Supernatant was carefully removed by aspiration.  
 
For mouse embryonic fibroblasts: 
24 hours before harvest, cells were detached with Trypsin. After resuspended in 
culture medium, cells were re-seeded in 12-well plates on glass cover slips and 
allowed to grow. Before harvest, medium was removed from the plates and cells were 
washed in 1x PBS.  
 
Afterwards, lymphoma cells or MEF were fixed immediately in freshly prepared 
fixation solution in order to avoid drying of the slide. After incubation (15´, RT), fixation 
solution was removed and cells were washed twice in PBS/MgCl2. Staining solution 
was added dropwise and slides were incubated in the dark in a 37°C incubator (10-16 
hours depending on the experiment). Afterwards, the staining solution was removed 
by aspiration. Cells were gently washed with 1x PBS and mounted while still wet. 
Slides were analyzed under the microscope and stored at 4°C. 
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3.2.9 Bacteriological work 
3.2.9.1 Transformation of bacteria 
Reagents, solutions and material 
 Competent E. coli (DH5) 
 Plasmid DNA (500 ng-1 μg) 
 LB medium 
 Pre-warmed LB plates (Ampicillin) 
Competent bacteria were thawed on ice. The desired plasmid DNA was added and 
mixed by gentle flicking of the tube.  The mixture was incubated on ice for 30´. 
Bacteria were heat shocked at 42°C for 1´ and immediately transferred to ice (5´). 1ml 
LB medium without antibiotic was added and bacteria were incubated at 37°C under 
gentle agitation for 60´. Bacteria were centrifuged (3000 rpm, 5´, RT) and pellet was 
carefully resuspended in 100 μl LB. Suspension was plated on an agar plates 
containing the right antibiotic and incubated over night at 37°C. Colonies were 
monitored and picked within one week when stored at 4°C. 
3.2.9.2 Plasmid DNA Mini-Preparation of bacterial culture 
Reagents, solutions and material 
 Bacteria plate from the transformed DH5 with the plasmid of interest 
 Pre-warmed LB medium including ampicillin (1 μg/ml) 
 Ice-cold Solution I including 100 μg/ml RNase A 
 Freshly prepared solution II 
 Ice-cold Solution III 
 2-propanol  
 70% Ethanol 
 dH2O 
A single colony of transformed bacteria was incubated in 2 ml LB medium with the 
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required antibiotic over night (37°C). Bacteria suspension was transferred to an 
Eppendorf tube, centrifuged at 3000 rpm (5´, 4°C). Medium was removed by 
aspiration and pellet was lysed by adding 100 μl ice-cold Solution I. Afterwards, 200 
μl of freshly prepared Solution II were added and mixed by inverting the tube several 
times. After 5´ of incubation on ice, 150 μl of ice-cold Solution III were added and 
dispersed through the viscous bacterial lysate by inverting the tube several times. 
After centrifugation (14000 rpm, 10´, 4°C), supernatant was transferred to a new 
Eppendorf tube and 0.4 ml of 2-propanol was added to precipitate DNA. After 
vortexing and centrifugation (14000 rpm, 10´, 4°C) the pellet was washed with 1 ml of 
70% Ethanol and centrifuged again (7500 rpm, 5´, 4°C). Pellet was air-dried and DNA 
was dissolved in 30 μl dH2O. The solution was gently vortexed for a few seconds. 
DNA concentration was measured with the Nanodrop Spectrophotometer. 
3.2.10 Transcriptome and clinical data analysis 
Microarray-based gene expression profiling of mouse lymphomas was conducted by 
Jan Dörr, Drs. Maja Milanovic, Julia Kase and Dido Lenze. 
 
For microarray-based gene expression profiling, RNA was isolated from untreated or 
5-day ADR-treated control;bcl2 E-myc lymphomas using the RNeasy minikit 
(Qiagen) and hybridized to Affymetrix Mouse Genome 430 2.0 microarrays 
(Affymetrix) according to the manufacturer’s instructions. The arrays were hybridized 
and washed in the GeneChip Fluidics Station 450, and signals were detected on an 
Affymetrix GeneChip Scanner 3000. Affymetrix files were imported into Partek 
Genomic Suite software (version 6.4, Partek, Inc.) and processed by the implemented 
robust multiarray (RMA) work flow (consisting of median polish probe set 
summarization, RMA background correction, and quantile normalization). The raw 
microarray data were deposited at the Gene Expression Omnibus (GEO) repository 
of the National Center for Biotechnology Information under the accession number 
GSE31099 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31099). For 
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further analysis of mouse microarray data, genetic signatures of NF-B activation 
were taken without further change from the Thomas Gilmore laboratoryWeb site (a 
complete list of genes and related references is available at 
http://www.bu.edu/nf-kb/gene-resources/target-genes). The enrichment of NF-B 
target gene sets within the global transcript signals from matched pairs of untreated 
versus ADR-treated control;bcl2 lymphoma cells was analyzed by applying the GSEA 
version 2.0 software (Broad Institute of the Massachusetts Institute of Technology 
and Harvard, http://www.broad.mit.edu/gsea). Normalized enrichment scores (NES) 
reflect a statistically significant enrichment for P-values <0.05 and FDR (false 
discovery rate) values <0.25 (Subramanian et al. 2005). 
 
Clinical data analysis was done in cooperation with the lab of Prof. Georg Lenz. 
 
Gene expression data of lymphoma biopsies from 233 patients, who were treated 
with R-CHOP-like immunochemotherapy and profiled using Affymetrix HG-U133 Plus 
2.0 microarrays (Lenz et al. 2008b), were obtained from the NCBI GEO (GSE10846). 
Patients were classified into ABC DLBCL, GCB DLBCL, and unclassified DLBCL 
according to Lenz et al (2008b). The 100 GCB DLBCL patient samples, for which 
clinical follow up information for progression-free survival was available, were equally 
divided into groups of high and low Bcl2 expression, based on the median expression. 
Within these two cohorts, patients were subsequently divided into high and low 
NF-B groups according to the median expression of a previously described NF-B 
gene expression signature consisting of 63 known NF-B target genes 
(http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signat
ureID=83; Shaffer et al. 2006). 
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3.3 Experimental setting 
To elucidate the function of the NF-B pathway in senescence, primary E-myc 
transgenic mouse lymphomas, a well-established model for human aggressive B-cell 
non-Hodgkin’s lymphomas (B-NHL) were stably transduced with the NF-B SR (or an 
empty vector as a control) as well as Bcl2 to prevent drug-induced apoptosis. After 
inhibition of the NF-B pathway and the induction of senescence by chemotherapy, 
growth effect and NF-B activity as well as SASP were measured in vitro (Fig. 10A). 
 
To further investigate the function of the NF-B pathway in senescence in vivo, Bcl2 
overexpressing lymphomas with/without NF-B inhibition were transplanted into 
syngeneic recipients by tail vein injection. When lymph nodes became palpable in 
recipient animals, mice were exposed to chemotherapy and lymphoma senescent 
ability was measured in situ (Fig. 10B). 
 
Additionally, to find out the subgroup of human lymphoma patients in which 
hyperactive NF-B contributes to treatment outcome, we applied a novel method- 
“cross-species investigations” in cooperation with the group of Prof. Georg Lenz 
(Charité). First, primary mouse lymphomas were characterized and genetically 
engineered according to distinct NF-B related oncogenic networks reminiscent of 
diffuse large B-cell lymphoma (DLBCL). Suggested by the results in the mouse 
lymphoma model, gene expression profiling of human diffuse large B-cell lymphoma 
samples at diagnosis were analyzed to identify the clinically relevant subgroup (Fig. 
10C). 
68 
Material and Methods 
69 
 
Fig 10: Experimental outline. (A) In vitro investigation of NF-B’s function in senescence. (B) In 
vivo investigation of NF-B’s function in senescence. (C) “Cross-species investigations” to identify 
a clinical relevant subgroup.
Results 
4 Results 
 
The experiments finished by collaborations are listed here: 
 
 Microarray-based gene expression analysis of mouse lymphomas was done by 
Jan Dörr, Drs. Maja Milanovic, Julia Kase and Dido Lenze. 
 
 Animal experiments were done by Drs. Soyoung Lee and Julia Kase. 
 
 Clinical data analysis was done in cooperation with the laboratory of Prof. Georg 
Lenz.
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4.1 NF-B activity is increased in therapy-induced 
senescence 
4.1.1 Therapy-induced senescence in lymphoma cells 
To assess the role of NF-B in senescence, an in vitro TIS model was established 
using primary Myc-driven B-cell lymphomas (referred to as ‘‘control’’ lymphomas) 
isolated from Eμ-myc transgenic mice (Schmitt et al. 2002 a). Although senescence 
can be induced by conventional chemotherapy in Myc-driven B-cell lymphomas, it is 
often masked by a faster apoptotic response. Therefore, primary lymphomas were 
stably transduced with bcl2 to prevent drug-induced apoptosis, and exposed to the 
DNA-damaging chemotherapeutic agent adriamycin (ADR). At day 5, ADR-treated 
control;bcl2 lymphomas were fully growth-arrested (Fig. 11A), stained negative for 
the proliferation marker Ki67, and uniformly exhibited senescence-associated 
-galactosidase activity (SA--gal) (Fig. 11B). 
 
Figure 11: Features of ADR-induced senescence in E-myc transgenic control lymphomas 
in vitro. (A) Growth curve analysis of ADR (50 ng/ml) treated-senescent vs. untreated (ut) 
control;bcl2 lymphomas presented as relative growth at day 5/day 0 (n = 5 samples each; 
histogram bars indicate mean values ± SDEV; * indicates P<0.05). (B) Representative 
photomicrographs of lymphoma samples as in A stained for SA--gal (top) or Ki67 (bottom); n > 
25 samples, scale bars indicate 50 μm. 
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4.1.2 Therapy-induced senescence is accompanied by 
NF-B activation 
Senescent cells are characterized by altered pattern of gene expression. To unveil 
TIS-related changes on the transcriptome level, genome-wide microarray gene 
expression profiles (GEPs) were generated from 12 matched pairs of primary 
control;bcl2 lymphomas that were either drug-senescent or untreated. Gene set 
enrichment analysis (GSEA) demonstrated that NF-B target genes as a whole, and 
NF-B-controlled cytokines in particular, were strongly skewed toward the TIS group 
(Fig. 12).  
 
 
 
Figure 12: Gene set enrichment analysis of ADR-senescent vs. untreated (ut) E-myc 
control;bcl2 lymphomas. Gene set enrichment analyses of NF-B targets (A) and the subset of 
cytokines and their modulators therein (B) in the GEP of ADR-senescent (ADR) vs. untreated (ut) 
E-myc control;bcl2 lymphomas (n = 12 matched pairs). 
 
In line with the increased transcription of NF-B target genes, the activation of the 
NF-B pathway is also characterized by enhanced DNA-binding activity. In matched 
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pairs of untreated versus senescent lymphomas, endogenous NF-B-DNA binding 
activity was analyzed in nuclear extract from lymphomas. Using a multiplex 
DNA-binding ELISA-based analysis, significantly higher DNA-binding activities for the 
four NF-B family subunits p50, p52, p65 (RelA), and RelB in senescent cells were 
detected, indicating that both the classical and the alternative NF-B pathways are 
activated in TIS (Fig. 13A). Matched-pair analyses of the p65 DNA binding activity in 
the same individual lymphomas are highlighted in Fig.13B. 
 
Figure 13: DNA binding activity of ADR-senescent vs. untreated (ut) E-myc control;bcl2 
lymphomas. (A) DNA binding activity of the indicated NF-B subunits in ADR-senescent and 
untreated (ut) E-myc control;bcl2 lymphomas (n ≥ 3 matched pairs per subunit; * indicates 
P<0.05). (B) Matched untreated/ADR-senescent lymphoma pairs for the p65 DNA binding activity. 
NF-B DNA binding activity was determined using TransAM™ NF-B Family ELISA Kit.  
 
Furthermore, a lunciferase-based assay also confirmed the higher DNA-binding and 
transcriptional activation of NF-B in senescent lymphomas. Primary control;bcl2 
lymphomas were stably transfected with the NF-B-luciferase reporter. After 
5-day-treatment with ADR, luciferase activity was measured in matched pairs of 
untreated versus senescent lymphomas. As shown in Figure 14, luciferase activity in 
senescent lymphoma was significantly higher than untreated lymphoma, indicating 
higher NF-B DNA binding and transcriptional activity in senescent cells. 
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Figure 14: Luciferase activity of an NF-B-luciferase reporter in ADR-senescent vs. 
untreated (ut) E-myc control;bcl2 lymphomas. E-myc control;bcl2 lymphomas were stably 
transfected with NF-B luciferase reporter plasmid, and exposed to ADR to induce senescence. 
The NF-B activity in lymphomas was measured by the luciferase activity assay. Firefly-luciferase 
activity was normalized to the amount of protein (n = 4; the data represent mean values ± SDEV; * 
indicates P<0.05). 
 
In accordance with the increased DNA binding activity of NF-B in senescent cells, 
immunofluorescence stained p65 in TIS lymphomas predominantly in the nucleus, 
while nonsenescent cells displayed a preferentially cytoplasmic localization (Fig.15A).  
In addition to nuclear translocation and enhanced DNA-binding activity of NF-B, 
optimal induction of NF-B target genes also requires phosphorylation of NF-B 
proteins, such as p65, within their transactivation domain by a variety of kinases in 
response to distinct stimuli. DNA-damaging agents, in addition to their ability to target 
IB degradation via an IKK-independent pathway, also lead to p65 phosphorylation 
at Ser536 (Viatour et al, 2005), which can be observed by immunoblot analysis. As 
expected, TIS lymphomas presented with induced expression levels of 
Ser536-phosphorylated p65 (p65-P-S536), indicating increased p65 transactivation 
capacity in senescent cells (Fig. 15B). 
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Figure 15: (A) Immunofluorescence of the NF-B subunit p65 in cytospin preparations of 
ADR-senescent vs. untreated (ut) E-myc control;bcl2 lymphomas (representative example of 
three cases analyzed; scale bars indicate 50 μm). (B) Immunoblot analyses of the indicated 
proteins in cell lysates from four matched lymphoma pairs. Whole cell lysates from lymphomas 
were evaluated by immunoblotting using antibodies specific for total p65, phospho-p65 
(p65-p-S536), H3K9me3 and -Tubulin. H3K9me3 serves as a senescence marker and -Tubulin 
serves as a loading control. 
 
To confirm NF-B activity at the level of individual target genes, the expression of 
transcripts that were among the differentially regulated gene products in the 
microarray analysis was measured by quantitative real-time PCR (RQ-PCR). For 
instance, IB, CycD2, c-Flip, Irf4 and Ccr7 are literature-defined NF-B signature 
genes for mouse and human lymphoma characterization (Davis et al. 2001). Il1, Il6, 
Cxcl1, CCL2 and Igfbp6 contain NF-B binding sites in their promoter region and 
belong to the SASP factors (Acosta et al. 2008; Kuilman et al. 2009). CXCR2 
(chemokine receptor 2), which is an NF-B target gene, reinforces the growth arrest 
of senescent cells in a positive feedback loop through its ability to boost the DNA 
damage response (Acosta et al. 2008). Igfbp7 is one of the secreted factors from 
senescent cells, but there is no NF-B binding site in its promoter region. As shown in 
Fig. 16, all NF-B target genes tested—non-secreted genes and SASP factors in 
particular—were expressed at higher levels in TIS compared with non-senescent 
lymphoma cells.  
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Figure 16: Quantitative real-time RT-PCR (RQ-PCR) analyses of the indicated non-secreted 
(A) and secreted transcripts (B) in lymphomas as in Figure 12 (n = 5 samples each). Total 
RNA was extracted and analyzed by RT-PCR with primer sets specific for the indicated transcripts. 
Shown are relative expression levels, normalized to an internal control (GAPDH), that are 
comparable throughout all data sets (note the log-scaled presentation in the cytokine panel). All 
histogram bars indicate mean values ± SDEV; * indicates P<0.05. 
 
Taken together, therapy-induced senescence exhibits a senescence-associated 
secretory phenotype. Activated NF-B signaling is a prominent feature of 
chemotherapy-related senescence in full-blown tumor cells. 
4.1.3 NF-B activity is increased in senescent mouse 
embryonic fibroblasts 
Using a simplified TIS model based on mouse embryonic fibroblasts (MEF), we 
further confirmed that the NF-B pathway is activated during the process of 
senescence. Mouse embryonic fibroblasts  were first stably transduced with myc 
and bcl2 to mimic the bcl2 overexpressing Eμ-myc transgenic lymphomas model, and 
then exposed to the DNA damaging chemotherapeutic agent adriamycin (ADR). MEF 
were harvested at the indicated time. The senescence phenotype, the NF-B 
pathway status and the SASP were tested in ADR-treated and untreated cells. As 
shown in Fig. 17, SA--gal-positive cells were detectable two days after ADR 
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treatment. Meanwhile, immunofluorescence staining of p65 in nuclei increased in 
ADR treated cells, indicating the nuclear translocation and also the increased 
expression of p65 in senescent cells. Four days after ADR treatment, with a 
persistent p65 nuclear localization, MEF uniformly exhibited SA--gal activity.  
 
 
 
Figure 17: ADR-induced senescence in MEF (myc - bcl2). (A) Photomicrographs of MEF 
stained for SA--gal at different time points (scale bars indicate 100 μm). (B) Nuclear translocation 
of p65 coincides with senescence. MEF overexpressing myc and bcl2 were treated with ADR 
(0.05 μl/ml) for the indicated time. Cells were stained with fluorescence-conjugated anti-p65 
antibodies and counterstained with DAPI (representative example of three cases analyzed; scale 
bars indicate 50 μm). 
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Furthermore, the expression of NF-B target genes, Ccl20, Mcp1, Il7 and Ptgs2 was 
detected by RQ-PCR at different time points. As show in Fig. 18, a higher expression 
level of the respective genes was detected two days after ADR treatment. Four days 
after treatment, all NF-B target genes tested were expressed at higher levels in 
senescent MEF compared with non-senescent cells. The high expression of Ccl20, 
Mcp1 and Il7, which encode NF-B target SASP factors, not only confirmed the 
activation of NF-B in senescent cells, but also indicated that SASP appear as a 
common feature of senescent cells.  
 
 
 
Figure 18: Quantitative real-time RT-PCR (RQ-PCR) analyses of the indicated NF-B target 
genes in MEF (myc - bcl2). Shown are relative expression levels, normalized to an internal 
control (GAPDH). All histogram bars indicate mean values ± SDEV; * indicates P<0.05.  
 
Taken together, the results in the simplified MEF model confirmed that NF-B 
signaling is activated in the process of therapy-induced senescence. 
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4.2 TIS depends on intact NF-B function in vivo 
4.2.1 Inhibition of the NF-B pathway ablates the SASP in 
TIS 
The data presented in 5.1. demonstrated that TIS cells display a 
senescence-associated secretory phenotype, and, in addition, are characterized by 
NF-B activation. Given the fact that many SASP factors contain NF-B binding sites 
in their promoter region, we predicted that the senescence-associated secretory 
phenotype is, at least partly regulated by the NF-B pathway. 
 
To address whether SASP depends on enhanced NF-B activity, a NF-B super 
repressor IB-ΔN (SR) - a nondegradable IB moiety, containing amino-acid 
residues 71–317 of IB-alpha (Krappmann et al. 1996) - was used to inhibit the 
NF-B pathway. E-myc control;bcl2 lymphomas were stably transfected with the SR 
or an empty vector as control and the expression of IB-ΔN was detected by 
immunoblot analyses. As shown in Fig. 19A, IB-ΔN was only detected in 
lymphomas transfected with the SR, but not in the control setting.  
 
Next, proper functionality of the SR was tested in a TNF-treatment setting. 
Lymphoma cells were treated with TNF- at 50 M for 24 hours and the expression 
levels of NF-B target genes were detected by RQ-PCR. In response to TNF-, 
NF-B target genes in lymphomas were induced and then further inhibited by SR 
(Fig.19B). Meanwhile, cells expressing the SR showed lower p65 signaling and no 
p65 nuclear translocation upon short-term TNF-treatment (Fig. 19C). To address 
the question whether the SR affects the proliferating character of lymphoma cells, 
proliferation of the lymphomas transduced with Vector or SR was assessed by a 
6-day growth curve under standard culture conditions as described in the Materials 
and methods section. The result suggests that SR has little impact on proliferation in 
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untreated lymphoma cells (Fig. 19D).  
 
 
Figure 19: Inactivation of NF-B by stable expression of IB-ΔN (SR). (A) Expression of 
NF-B super repressor IkBa-ΔN (SR) in three matched lymphoma pairs detected by Immunoblot 
analyses. Thirty micrograms of whole cell lysate from lymphomas stably transfected with empty 
vector (Vector) or IB-ΔN (SR) were evaluated by immunoblotting using antibodies specific for 
IB and -Tubulin. (B) RQ-PCR analyses of the indicated transcripts after 24 hours of TNF- 
treatment (n = 5 samples each). (C) Proper functionality of the NF-B super repressor IB-ΔN 
(SR) in TNF--exposed E-myc lymphoma cells, as demonstrated by the inhibition of nuclear 
translocation of the NF-B subunit p65 after 30 minutes (anti-p65 immunofluorescence with DAPI 
as nuclear counterstaining; representative example of three independent cases, scale bars 
indicate 50 μm).  (D) Growth curve analysis of untreated control lymphomas stably expressing 
the SR or vector-infected (representative comparison of one individual lymphoma ± SR shown; n 
= 5 samples). 
 
Then the SR was further used to investigate the function of NF-B regarding the 
Results 
senescence-associated secretory phenotype. Control;bcl2 lymphomas stably 
expressing the SR or the empty vector were treated with ADR for 5 days to induce 
senescence. Gene expression was determined by real-time PCR and normalized by 
the level of GAPDH as an internal control. Because the initial fold induction after ADR 
treatment varied in such a large scale, to facilitate easy comparison, the relative 
expression levels of ADR-treated cells compared to UT cells (ADR/UT) was 
calculated first and this value of SR cells was compared to that of vector control, to 
get the fold reduction. In treatment induced senescence, the expression of most 
NF-B target genes—both SASP and nonsecreted genes—was sharply reduced in 
the ADR-exposed SR engineered control;bcl2 lymphoma group, as further highlighted 
in matched-pair analyses of the same individual lymphomas with or without the SR 
moiety for representative NF-B-controlled SASP factors (Fig. 20). 
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Figure 20: The expression of NF-B target genes in the ADR-exposed SR/empty 
engineered control;bcl2 lymphoma group. (A) RQ-PCR analyses of the indicated transcripts in 
lymphomas presented as the ratio of the relative values for ADR-exposed vs. untreated 
control;bcl2 lymphomas stably expressing the NF-B super-repressor IB-ΔN (SR) or being 
empty vector-infected as a control (at least five samples each). (B) Matched ADR-exposed 
control;bcl2 lymphoma pairs ± SR shown for the relative expression levels of two representative 
SASP factors. 
 
Likewise, NF-B inhibitors also prevent the induction of SASP factors in senescent 
cells. Control;bcl2 lymphoma cells were treated with ADR in combination with a 
Results 
variety of pharmacological NF-B inhibitors and the expression levels of NF-B 
targets were measured. As shown in Fig. 21, Bay11-7082, an IB phosphorylation 
inhibitor, suppressed the expression of Il1, Il6, Cxcl1, Cxcr2, Ccl2 and Gm-csf in 
senescent cells. TPCA-1 and KINK-1, both are IKK-2 inhibitors, suppressed the 
expression of Il1, Il6 and Gm-csf, but not other genes tested in senescent cells, 
suggesting that Bay11-7082 is a more efficient NF-B inhibitor.  
 
Fig. 21: RQ-PCR analyses of the indicated transcripts in lymphomas presented as the ratio 
of the relative values for ADR-exposed vs. untreated control;bcl2 lymphomas, with or 
without preceding exposure to the indicated pharmacological NF-B inhibitors (i.e. 
Bay11-7082 [Bay; left], TPCA-1 [center], and KINK-1 [right]; at least five samples each). 
Note that values are not comparable between inhibitor panels, because different individual 
lymphomas were used. All histogram bars indicate mean values ± SDEV. 
 
In summary, NF-B acts as a master regulator of the SASP in therapy-induced 
senescence, as revealed by genetic and pharmacological inhibition of the NF-B 
pathway. 
4.2.2 Inhibition of the NF-B pathway ablates the SASP in 
radiation-induced senescence 
In addition to chemotherapy, senescence can also be induced by radiation therapy. 
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The results in primary lymphoma cells demonstrate that the senescence-associated 
secretory phenotype depends on NF-B activation. To address the question whether 
the dependency of the SASP on NF-B signaling is a common mechanism or a 
context-dependent phenomenon, mouse embryonic fibroblasts were subjected to 
ionizing radiation to induce senescence. Ten days after irradiation, MEF were fully 
growth-arrested and exhibited senescence-associated -galactosidase activity. 
Meanwhile, senescent MEF showed the senescence-associated secretory phenotype 
Fig. 22A and C).   
 
Figure 22: The SASP depends on NF-B signaling in irradiation-induced senescence. (A) 
RQ-PCR analyses of the indicated transcripts in MEF ten days after irradiation vs. untreated MEF. 
Changes are expressed as fold of induction relative to untreated MEF. (B) Ten days after 
irradiation, RQ-PCR analyses of the indicated transcripts in MEF presented as the ratio of the 
relative values for radiation-exposed vs. untreated MEF stably expressing the NF-B 
super-repressor IB-ΔN (SR) or being empty vector-infected as a control. Shown are relative 
expression levels, normalized to an internal control (GAPDH). All histogram bars indicate mean 
values ± SDEV. (E) Photomicrographs of MEF stained for SA--gal at the indicated days (scale 
bars indicate 100 μm). Note that the gene expression pattern of SASP in MEF and lymphomas is 
slightly different. 
Results 
To understand the function of NF-B in SASP in the radiation-induced senescence 
model, the stably expressed NF-B super repressor IkBa-ΔN (SR) was used to inhibit 
the NF-B pathway. The expression of SASP factors was tested in irradiated and 
untreated MEF at different time points. The real-time PCR results demonstrate that 
NF-B inhibition sharply reduced the expression levels of NF-B targeted SASP 
factors (Fig. 22B). Meanwhile, the percentage of SA--gal positive cells is slightly 
lower in the irradiated SR engineered MEF (Fig 22C). These findings suggest that 
NF-B activation is necessary for secretion of at least some SASP components in 
MEF. These data, together with previous results on lymphomas, indicate that the 
dependency of SASP on the NF-B pathway is a common mechanism. 
4.2.3 TIS depends on intact NF-B function 
The obvious next question was whether TIS not only presents with enhanced NF-B 
activity, but also depends on it. The senescence capability of lymphomas expressing 
the NF-B superrepressor IBa-ΔN (SR) was tested in vitro. SA--gal-based 
analyses of matched pairs differing only in their SR status revealed a spectrum that 
reached from a substantial decline in the percentage of SA--gal-positive cells in 
some to an uncompromised TIS phenotype in other lymphomas of the SR cohort, 
reflecting a mean reduction of SA--gal reactivity by >30% (Fig. 23A). Collectively, 
these data suggest a modest contribution of putative pro-senescent NF-B-governed 
functions in a homotypic tumor cell population—Irrespective of their intracellular, 
autocrine, or paracrine modes of action (Acosta et al. 2008; Kuilman et al. 2008) - at 
least in a subset of genetically susceptible primary tumors. Rather than functioning as 
a linear and essential component of the DDR-initiated senescence pathway, it is very 
well conceivable that the NF-B network operates as a corroborating, collateral relay 
of the prosenescent DDR. In such a scenario, the uniform exposure of all cells to a 
chemotherapeutic agent in culture would probably launch such a strong DDR 
cascade in every given cell that a quantitative reduction of a senescence-reinforcing 
principle by the SR will not instantly translate into a senescence-defective phenotype 
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—except collateral prosenescent pathways became dysfunctional, thereby making 
the contribution of NF-B signaling to TIS critical. 
 
 
 
Figure 23: TIS depends on intact NF-B function. (A) Frequencies of SA--gal-positive cells 
from matched lymphoma pairs ± SR, exposed to ADR in vitro (n = 7 pairs). (B) In situ-frequencies 
of SA--gal-positive as well as Ki67-positive cells in matched-pair (± SR) lymphoma sections, 
exposed to CTX in vivo (n = 3 pairs; representative photomicrographs shown, scale bars reflect 
100 μm). All histogram bars or numbers indicate mean values ± SDEV. 
 
The in vivo situation is by far more complex, including aspects such as 
inhomogeneous drug delivery and heterotypic cell–cell interactions that were not 
covered by in vitro analyses. To address the potential contribution of NF-B activity to 
a drug-inducible senescence phenotype in a scenario most closely recapitulating the 
natural tumor situation, genetically compatible transplant lymphomas were 
investigated in vivo. Control;bcl2 lymphomas retrovirally infected with the SR 
construct or an empty vector for comparison were transplanted into normal, 
immunocompetent recipient mice, where they formed systemic lymphomas 
indistinguishable from the primary transgenic host they were initially derived from. At 
the time a peripheral lymphadenopathy became palpable, mice harboring a 
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comparable tumor burden were treated once with the DNA-damaging anti-cancer 
agent cyclophosphamide (CTX), and lymphomas were analyzed for in situ signs of 
TIS 5 days later. Intriguingly, while control lymphomas showed a strong SA--gal 
reactivity and less than 20% Ki67-positive cells, TIS-competent SR lymphomas 
presented with virtually no SA--gal reactivity and >80% Ki67-positive cells following 
CTX exposure in vivo (Fig. 23B). 
 
Therefore, SR-expressing lymphomas displayed a much more profound TIS defect in 
vivo, even if they exhibited only some reduction of their SA--gal reactivity in vitro, 
indicating a critical, NF-B-dependent prosenescent contribution of bystander cells 
within the tumor microenvironment. Of note, senescence-associated interaction with 
host immune cells is cocontrolled by NF-B activity as well (Chien et al. 2011; Xue et 
al. 2007), thereby suggesting immune-mediated clearance of senescent cells as 
another link by which NF-B may control tumor growth. Taken together, the NF-B 
network operates as a critical component of the drug-inducible senescence response, 
whereby the actual quantitative impact of its interference with cell-autonomous and 
non-cell-autonomous senescence-relevant processes can only be appreciated in 
vivo. 
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4.3 Oncogenic networks determine opposing roles of 
NF-B on treatment outcome 
In human diffuse large B-cell lymphoma, the ABC subgroup is associated with 
constitutive activation of NF-B and has poor treatment outcome. It is reported that 
the ability of NF-B to inhibit responses to cancer therapeutic agents may contribute 
to the refractory clinical behavior of ABC DLBCL (Baldwin et al. 2001). Our data in 
mouse lymphoma model unveiled that the NF-B network operates as a critical 
component of the drug-inducible senescence response. Since senescence 
contributes to the outcome of cancer therapy, we asked the question whether 
hyperactive NF-B contributes to treatment outcome in human lymphoma patients. 
To find the subgroup in which hyperactive NF-B benefits the treatment outcome, 
primary mouse lymphomas were characterized and genetically engineered according 
to distinct NF-B-related oncogenic networks reminiscent of diffuse large B-cell 
lymphoma. 
4.3.1 NF-B-mediated chemoresistance results in poor 
treatment outcome in ABC-reminiscent lymphomas 
To quantify and dissect the contribution of NF-B signaling to the long-term outcome 
of naturally formed B-cell lymphomas prior to any therapy, twelve primary E-myc 
lymphomas were grouped according to endogenous NF-B activation assessed by 
nuclear p65 DNA-binding ELISA. Accordingly, lymphomas were grouped as an 
‘‘NF-B low’’ (NL, the four lowest cases) and an ‘‘NF-B high’’ (NH, the four highest 
cases) cohort (Fig. 24).  
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Figure 24: Classification of primary control lymphomas by the NF-B status. Stratification of 
twelve primary control lymphomas in an “NF-B low” (NL; black bars), an intermediate (grey bars), 
and an “NF-B high” (NH; white bars) group according to their NF-B p65 DNA binding activities 
at diagnosis. Primary lymphoma cells were cultured for 24 hours in vitro to eliminate normal cell 
contamination. Nuclear extracts were prepared, and 5µg of the nuclear extract protein was used 
for ELISA-based DNA binding assay (measured in triplicate; horizontal lines indicate mean activity 
within the respective group).  
 
Constitutive activation of NF-B is an important anti-apoptotic mechanism in B-cell 
lymphomas with poor prognosis. Therefore, the apoptotic potential of these 
lymphomas was detected by their short-term drug sensitivity. Lymphomas were 
treated in vitro with 5 ng/ml of ADR for 24 hours and cell viability was measured by 
trypan blue. Expectedly, the NH group was virtually resistant to ADR, while lymphoma 
cells of the NL group quantitatively died at the same dose level (Fig. 25A).  
 
Since Bcl2 is frequently detected at overexpressed levels in human B-cell lymphomas 
and a bona fide NF-B target, we reasoned that chemoresistance in NH lymphomas 
might be mediated, at least in part, via induction of Bcl2 (Schmitt et al. 2000； 
Feuerhake et al. 2005). Indeed, Bcl2 transcript levels, measured by RQ-PCR, were 
significantly higher in the NH compared with the NL group (Fig. 25B).  
Results 
90 
 
 
 
Figure 25: Bcl2 mediates treatment resistance in lymphomas. (A) Viability analysis by trypan 
blue dye exclusion of the NL vs. NH lymphoma cell populations exposed in vitro for 24 hours to 5 
ng/ml of ADR relative to untreated cells of the same group (n = 4 each group). (B) RQ-PCR 
analyses of the transcript levels of the NF-B target bcl2 in the NH and NL lymphoma groups 
(Histogram bars indicate mean values ± SDEV; * indicates P<0.05). 
 
Accordingly, when lymphoma cells were co-treated with ADR and Abt-737 (a BH3 
mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL), The 
NH group regained chemo-sensitivity, while the NL group did not significantly change 
(Fig. 26A). Likewise, at the dose level that NL group showed no significant difference 
in cell viability, cell viability of NH group decreased significantly under the 
co-treatment of ADR and Abt-263 (structurally related to ABT-737, a disruptor of 
Bcl-2/Bcl-xL interactions) (Fig. 26B). 
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Figure 26: NF-B high lymphomas (NH) are more sensitive to Bcl2 inhibition. (A) Viability 
analysis by trypan blue dye exclusion of the NL (n = 4) vs. NH (n = 3) lymphoma cell populations 
exposed in vitro for 24 hours to 5 ng/ml of ADR, 0.1 μM ABT-737, or 5 ng/ml of ADR and 0.1 μM 
ABT-737 relative to untreated cells of the same group. (B) Viability analysis by trypan blue dye 
exclusion of the NL (n = 4) vs. NH (n = 3) lymphoma cell populations exposed in vitro for 24 hours 
to 5 ng/ml of ADR, 0.5 μM ABT-263, or 5 ng/ml of ADR and 0.1 μM ABT-263 relative to untreated 
cells of the same group. 
 
Moreover, retroviral overexpression of Bcl2 rendered NL lymphomas as 
chemoresistant as NH lymphomas (Fig. 27A).  Conversely, we asked whether 
inhibition of NF-B activity might overcome the short-term drug resistance in the NH 
group. While inactivation of NF-B function by the SR moiety had little impact in the 
NL group, it restored chemosensitivity in the NH group, thereby uncovering highly 
active NF-B signaling as an ‘‘Achilles’ heel’’ of this group during chemotherapy (Fig. 
27B).  
 
Taken together, a proportion of primary Myc-driven lymphomas presents with 
high-level NF-B activity at diagnosis, suggestive for an oncogenic function of the 
NF-B pathway selected for during lymphoma development that simultaneously 
anticipates primary drug resistance. 
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Fig 27: NF-B-driven, high Bcl2 expression mediates treatment resistance in lymphomas. 
(A) Viability analysis as in Figure 25A and with the same lymphoma samples, now overexpressing 
Bcl2 from retroviral alleles in both groups. (B) GFP enrichment analysis of 
MSCV-SR-IRES-GFP-expressing cells treated as in Figure 25A, but for 48 hours; selective drop 
of GFP-positive cells in the NH group indicating their increased chemosensitivity upon NF-B 
inhibition (n = 3 each group). All histogram bars indicate mean values ± SDEV. 
 
Recapitulating the clinical outcome of patients suffering from DLBCL, 60% of the 
mice harboring E-myc control lymphomas achieve long-term remissions (reflecting 
cure), while the remaining 40% encounter a relapse after cyclophosphamide (CTX) 
induction therapy (Schmitt et al. 1999, 2000; Lenz et al. 2008). To generate 
‘‘time-to-relapse’’ data, 13 primary (not bcl2-infected) E-myc lymphomas were 
transplanted into recipient mice and exposed to CTX at the time of lymphoma 
manifestation. While all animals entered a remission, seven lymphomas relapsed 
within the 100-day observation period. Therefore, the 13 lymphomas at diagnosis 
were grouped as either ‘‘never relapse’’ (NR) or ‘‘relapse prone’’ (RP). Based on the 
previous results, we assessed basal NF-B activity by the expression of two NF-B 
targets, IB and Bcl2 in untreated lymphomas of these two groups (Fig. 28). 
Strikingly, RP lymphomas were found to exhibit significantly higher IB expression 
levels, further accompanied by substantially higher bcl2 expression levels, thus 
reminiscent of the NF-B/Bcl2 network analyzed before and of the genetic hallmark 
Results 
lesions detectable in activated B-cell like (ABC) DLBCL, the prognostically inferior 
DLBCL subtype characterized by constitutively active NF-B signaling due to a 
variety of activating mutations in the NF-B pathway and by very high Bcl2 transcript 
levels (Iqbal et al. 2006; Lenz et al. 2008b; Compagno et al. 2009; Staudt 2010; 
Nogai et al. 2011). 
 
Figure 28: Grouping of 13 primary control lymphomas according to the long-term responses to 
CTX therapy following transplant tumor formation in vivo as either “never relapse” (NR) or 
“relapse prone” (RP) lymphomas. RQ-PCR analyses of their IB transcript levels at diagnosis 
(i.e. prior to any therapy) as a representative bona fide NF-B target (A), and of bcl2 levels of the 
same samples (B); presented in the same order); horizontal lines indicate mean activity within the 
respective groups.  
4.3.2 ABC-reminiscent lymphomas show a senescence 
defect  
In addition to apoptosis, senescence is another drug-responsive effector program of 
cancer therapy. Since NF-B-driven-high Bcl2 expression blocks apoptosis in 
ABC-reminiscent lymphomas, we asked whether high NF-B activity contribute to 
senescence in this group. To address this question, Bcl2-overexpressing NL 
lymphomas, NH lymphomas and p53 null lymphomas were treated with ADR. At day 
5, senescence was analyzed by SA--gal and Ki67 staining. Unlike the expectation 
that high NF-B activity would lead to more TIS, NH lymphomas displayed less 
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SA--gal positive cells and a high Ki67 index after ADR treatment in comparison with 
NL lymphomas (Fig. 29), which suggest that NH lymphomas are, at least partly, 
deficient to enter senescence upon cancer therapeutic agent treatment. 
 
 
 
Figure 29: ABC-reminiscent lymphomas show a senescence defect upon treatment. (A) 
Frequencies of SA--gal-positive cells in ADR-treated vs. untreated (ut) Bcl2-overexpressing NL 
lymphomas (n = 6), NH lymphomas (n = 6) and p53 null lymphomas (n = 4). Lymphomas were 
exposed for 5 days to 50 ng/ml ADR in vitro. Representative photomicrographs of cytospin 
preparations are shown underneath the corresponding bars. (B) Frequencies of Ki67-positive 
cells in ADR-treated vs. untreated (ut) Bcl2-overexpressing NH lymphomas (n = 6). NH 
lymphomas were exposed for 5 days to 50 ng/ml ADR in vitro. Representative photomicrographs 
of cytospin preparations are shown underneath the corresponding bars. Note that the number of 
lymphomas in NL and NH group was expanded according to the NF-B p65 DNA binding 
activities. 
 
Although the detailed mechanism still needs to be investigated, there are several 
possible explanations for this phenotype. Reportedly, numerous genetic 
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abnormalities in the ABC subtype are rare or absent in the GCB subtype. Among 
these genetic abnormalities, the INK4a/ARF tumor suppressor locus was 
homozygously or hemizygously deleted in 30% of ABC DLBCL but in only 4% of GCB 
DLBCL (Lenz et al. 2008c). Since genomic INK4a/ARF deletions directly disable 
therapy-induced senescence (Schmitt et al. 2002a), analyzing the INK4a/ARF defects 
in NH and NL lymphomas might provide an explanation for the senescence defect 
phenotype in ABC-reminiscent lymphomas. Another explanation is that instead of 
hyperactive NF-B per se, the capability to be further activated upon chemotherapy is 
crucial for the induction of senescence.  
4.3.3 The NF-B-mediated pro-senescence function 
contributes treatment outcome in GCB DLBCL with high 
Bcl2 expression  
In contrast to ABC DLBCL, germinal center B-cell-like (GCB) DLBCL present with a 
much better clinical outcome (Lenz et al. 2008b), although Bcl2 overexpression is 
common in this subtype as well. Importantly, GCB DLBCL rarely possess activating 
NF-B mutations, but frequently (45%) develop in the context of a t(14;18) 
translocation that drives bcl2 overexpression via the immunoglobulin heavy chain 
locus in an NF-B-independent fashion, a lesion that is virtually never found in 
ABC-type DLBCL (Nogai et al. 2011), thereby creating an entirely differently wired 
“NF-B/Bcl-2” oncogenic network. When drug-inducible apoptosis is blocked in 
mouse lymphomas by exogenous Bcl2 overexpression, thereby mimicking the 
GCB-related t(14;18) translocation, NL (GCB-reminiscent) lymphomas were able to 
enter TIS (Fig. 29). To test whether higher NF-B activation levels would further 
promote senescence induction in these lymphomas, a strongly NF-B-activating 
CARD11 (also known as CARMA1 or Bimp3) mutant, the murine homolog of the 
human CARD11-L244P mutant, was used to modify the NF-B pathway. 
Overexpression of CARD11-L251P mutant resulted in increased NF-B target gene 
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expression (Fig. 30A; Lenz et al. 2008a).  
 
Figure 30: Higher NF-B activity may contribute to treatment outcome via TIS promotion. 
(A) Enhanced NF-B target gene expression in response to the oncogenic CARD11-L251P 
mutant, but not to wild-type (wt) CARD11. RQ-PCR analyses of IL-6 and IB transcripts in an 
E-myc control lymphoma stably transduced with the CARD11-L251P mutant, wild-type CARD11 
or empty vector-infected for comparison (representative pattern of induction shown for one 
individual lymphoma out of four tested). (B) Frequencies of SA--gal-positive cells in 
Bcl2-overexpressing NL lymphomas ± CARD11-L251P, exposed for 3 days to 50 ng/ml ADR in 
vitro (n = 4 matched pairs; representative photomicrographs of cytospin preparations shown 
underneath the corresponding bars). Note that CARD11-L251P did not induce senescence in the 
absence of ADR. 
 
While naturally occurring CARD11 mutations are preferentially found in ABC DLBCL, 
here, such a mutant was used to enhance NF-B activity in a ‘‘GCB-reminiscent’’ 
lymphoma cohort, which formed in the absence of highly activated NF-B and where 
apoptosis is blocked independently of NF-B via autochthonous Bcl2 overexpression. 
Indeed, at an early time, when ADR-exposed Bcl2-engineered NL lymphomas were 
still largely negative for signs of TIS, a high proportion of the matching, mutant 
CARD11-overexpressing lymphoma cells already stained positive for SA--gal 
activity (Fig. 30B), suggesting that induced NF-B activity promotes TIS. 
 
Results 
Therefore, higher NF-B activity mediates a pro-senescence function in 
Bcl2-overexpressing GCB reminiscent mouse lymphomas. It is reasonable to predict 
that high NF-B activity contributes to superior treatment outcome via TIS promotion 
in bcl-2-high-expressing GCB DLBCL.  
 
Suggested by the results in E-myc transgenic lymphoma model, we decided to 
interrogate a large data set of GEP and clinical data after rituximab-CHOP-like 
standard immunochemotherapy (which includes both ADR and CTX) from 233 
DLBCL patients (Lenz et al. 2008b), and asked in the subset of GCB DLBCL patients 
with high Bcl2 expression (i.e. Bcl2 transcript level above median) whether a 
previously identified NF-B gene expression signature consisting of 63 known NF-B 
target genes would allow us to stratify two patient cohorts with different clinical 
outcome (Shaffer et al. 2006). Indeed, as shown in Fig. 31A, Bcl2-overexpressing 
GCB DLBCL patients with an NF-B signature expression above median (NH; n = 25) 
had a significantly superior progression-free survival when compared with the 
complementary group with lower NF-B signature expression (n = 24; P < 0.005), 
while such a correlation was not found in patients harboring high Bcl2-expressing 
lymphomas of the ABC subtype (Fig. 31B) or lymphomas of either subtype with low 
Bcl2 expression. Notably, multivariant analysis indicated that the NF-B status in 
Bcl2-overexpressing GCB DLBCL cases was statistically independent of the 
International Prognostic Index overall score (P = 0.3956), which is used as a clinical 
standard to predict outcome in lymphoma patients (The International Non-Hodgkin’s 
Lymphoma Prognostic Factors Project 1993).  
 
Taken together, this innovative experimental strategy-termed “cross-species” 
investigation-led to the identification of a genetically defined and clinically significant 
subgroup of GCB DLBCL patients who experienced superior treatment outcome if 
NF-B signaling was hyperactive, thereby contrasting the well-established 
association of the ABC subtype with constitutively active NF-B signaling and poor 
treatment outcome. 
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Figure 31: The relation of NF-B signature and the outcome in DLBCL patients (A) Bcl2-high 
GCB DLBCL patients experience a significantly longer progression-free survival if NF-B is 
hyperactive in their lymphomas. Progression-free survival of the 49 R-CHOP-like-treated GCB 
DLBCL patients from a total of 233 patients (as reported by Lenz et al. (Lenz et al. 2008b)) with an 
above median bcl2 expression by microarray based transcriptome analysis of their lymphomas at 
diagnosis, and further stratified by a 63-gene signature as either “NF-B high” (NH, n = 25, green) 
or “NF-B low” (NL, n = 24, blue). All histogram bars indicate mean values ± SDEV. (B) The 
NF-B signature fails to stratify the outcome of ABC DLBCL patients with high Bcl2 expression to 
R-CHOP-like induction therapy. Progression-free survival of the 45 R-CHOP-like-treated ABC 
DLBCL patients from a total of 233 patients (as reported by Lenz et al. (Lenz et al. 2008b)) with an 
above median bcl2 expression by microarray-based transcriptome analysis of their lymphomas at 
diagnosis, and further stratified by the 63-gene signature as either “NF-B high” (NH, n = 22, 
green) or “NF-B low” (NL, n = 23, blue). 
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5 Discussion 
5.1 NF-B’s function in cellular senescence 
Ever since the identification of senescence as a stable growth arrest with potential 
implications in aging, its physiological relevance has been expanded as stresses like 
oncogenes, ionizing radiation or exposure to chemotherapeutic drugs were also 
found to activate senescence. Similar to apoptosis, cellular senescence has been 
demonstrated to function as a tumor suppressor mechanism, preventing the 
accumulation of cells that encountered signaling imbalances and other transforming 
events. Moreover, senescence also contributes to the outcome of cancer therapy in 
vivo (Schmitt et al. 2002a and Haugstetter et al. 2010).  
 
Activated NF-B signaling has mostly been linked to treatment resistance, especially 
when the inability to enter drug-induced apoptosis was measured in short-term 
assays (Wang et al. 1999). Tumors with constitutive NF-B activation usually show 
increased resistance to chemotherapy.  
 
Previous studies linked oncogene-induced senescence to the massive production of 
a large variety of cytokines, such as interleukins, GM-CSF, bFGF, CXCL-1/-2/-3/-5/-7 
and MCP-1. Many of these SASP factors possess NF-B-binding sites in their 
promoters. Using Bcl2-overexpressing primary Eμ-myc transgenic mouse lymphoma 
cells, we revealed a dramatic induction of non-secreted and secreted NF-B target 
genes during TIS, and, importantly, a dependency of the senescent phenotype on 
functional NF-B signaling that becomes particularly evident in vivo—a finding in full 
agreement with related work by Chien and colleagues (Chien et al. 2011).  
 
As discussed in the former part of this thesis, therapy-induced senescence is 
accompanied by a senescence-associated secretory phenotype, as well as NF-B 
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activation, which was demonstrated by GSEA of NF-B target genes, NF-B nuclear 
translocation and DNA-binding activity analysis. Our results unveiled that activated 
NF-B signaling is a prominent feature of chemotherapy-induced senescence. 
 
Reportedly, NF-B is a multi-functional transcription factor and involved in many 
processes like cell survival, growth, stress response, and inflammation. The fact that 
NF-B is activated during treatment-induced senescence implies its regulatory role in 
this process. Indeed, enforced NF-B activation by mutant Card11 accelerated TIS in 
vitro. However, individual lymphoma reacts differently to NF-B inhibition in vitro. We 
observed a substantial decline in the percentage of SA--gal-positive cells in some 
lymphomas of the SR cohort compared with controls while in others the 
uncompromised TIS phenotype was not affected. The incomplete ablation of 
senescence phenotype in vitro suggests that instead of being a linear and essential 
component of the DDR-initiated senescence pathway, NF-B operates as a 
corroborating, collateral relay of the prosenescent DNA damage response. 
Surprisingly, we observed a much more pronounced impairment of TIS following 
NF-B inhibition in vivo. The virtual absence of senescence in NF-B-defective 
lymphoma cells at a time when NF-B-competent lymphomas became largely 
senescent indicates additional, non-cell-autonomous implications of NF-B signaling 
in the senescence process. Compared with the in vitro situation, the in vivo 
environment is more complex, including paracrine modes of action and crosstalk to 
other, non-malignant cell types. As recent studies revealed certain secreted factors, 
such as TGF-beta (Reimann et al. 2010) and IL8 (human) (Acosta et al.2008) as 
potential senescence inducers, NF-B is possibly involved in the process of 
senescence induced by prosenescent factors released by adjacent cells in vivo. 
 
The senescence program involves a complex interplay between intracellular and 
extracellular processes that influence the cell cycle arrest, the tissue 
microenvironment, and the surveillance of senescent cells by various immune system 
components. Senescent cells communicate with their environment by secreting 
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various cytokines and growth factors, and it was reported that the secretory 
phenotype could reinforce the senescence arrest and mediate cross-talk between 
senescent cells and other cells within their microenvironment. As a major regulator of 
SASP, NF-B is involved not only in the stabilizing cell cycle arrest but also in 
promoting immune cell clearance (Chien et al, 2011). Chien and colleagues 
demonstrated that disruption of the SASP through NF-B inhibition promotes 
chemoresistance of lymphomas mainly through a failure to engage the senescence 
response and to trigger immune clearance of the senescent cells. Consequently, 
animals harboring lymphomas with suppressed NF-B show early relapse and poor 
survival post-therapy. Given the large number of genes regulated by NF-B, it is quite 
possible that NF-B functions as a tumor suppressor in a microenvironment 
consisting of senescent cells, factors secreted by senescent cells and non-malignant 
bystanders, particularly immune cells. 
5.2 Dark side of NF-B—anti-apoptosis 
NF-B regulates important cellular processes ranging from establishment of the 
immune and inflammatory responses to regulation of cell proliferation or apoptosis 
through the induction of a large array of target genes. Until now, NF-B has been 
considered as an important factor in the tumorigenic process mainly because it exerts 
strong anti-apoptotic functions in cancer cells. Recent studies have shown that B-cell 
lymphomas frequently harbor genetic mutations in NF-B pathway components 
resulting in constitutive, and presumably oncogenic, NF-B signaling by establishing 
a prosurvival phenotype (Staudt et al, 2010). Numerous studies have demonstrated 
that inhibition of NF-B by different means increased sensitivity of cancer cells to the 
apoptotic action of diverse effectors such as TNF, chemo-, or radiotherapies (Wang 
et al. 1996; Jung et al. 2001; Smirnov et al. 2001). From these studies emerged the 
concept that NF-B blockade could be combined to conventional therapies in order to 
increase therapy efficiency. Although our results demonstrate an essential role for 
NF-B in the induction of cellular senescence in a genetically defined model scenario, 
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the net impact of NF-B on treatment outcome in natural tumors is much more difficult 
to assess.  
 
Human DLBCL can be divided into at least two subtypes according to their 
gene-expression profiling: ABC DLBCL and GCB DLBCL. Compared to GCB, the 
ABC subtype exhibits constitutive activation of the NF-B pathway and presents with 
inferior clinical treatment outcome. The fact that ablation of NF-B in cell lines derived 
from ABC DLBCL, but not in GCB DLBCL, led to apoptosis suggests that NF-B 
activation plays a critical role in the oncogenic phenotype of ABC DLBCL. Based on 
human DLBCL data linking the ABC subtype to activating NF-B lesions and an 
inferior outcome to standard immunochemotherapy (Lenz et al. 2008b; Compagno et 
al. 2009), we classified a series of primary E-myc transgenic lymphomas with known 
long-term responses to chemotherapy in vivo based on their NF-B activity levels at 
manifestation. Reminiscent of GCB-type DLBCL, the group of E-myc lymphomas 
with good clinical outcome was largely composed of lymphomas exhibiting low basal 
NF-B activity. Importantly, the group of Eμ-myc lymphomas with high NF-B activity 
exhibited high Bcl-2 expression, which correlated with chemoresistance. By Bcl-2 
inhibition on top of chemotherapy, we were able to demonstrate that high Bcl-2 
expression driven by NF-B is responsible for the chemoresistance in ABC 
reminiscent group. These results are in accordance with the NF-B’s anti-apoptotic 
function in the ABC subtype of human diffuse large B-cell lymphoma. More 
importantly, restoring treatment sensitivity by inhibiting Bcl-2 or NF-B suggests that 
NF-B/Bcl-2 is a potential treatment target in this subgroup. 
 
NF-B-activating mutations acquired during lymphoma development, as preferentially 
observed in the ABC subtype of DLBCL, account for the selective vulnerability of 
these lymphomas to NF-B inhibitors or shRNAs targeting components of the NF-B 
pathway (Davis et al. 2001; Ngo et al. 2006). Since the anti-apoptotic bcl2 gene is a 
bona fide NF-B target, ABC DLBCLs are genetically determined to depend on an 
NF-B-to-Bcl2 signaling module (a linear, two-factor oncogenic network model). The 
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highly active NF-B signaling is an ‘‘Achilles’ heel’’ of this group and is an ideal target 
for cancer therapy. 
5.3 Beneficial side of NF-B—prosenescence 
Unlike ABC DLBCL, in which an NF-B/Bcl2 signaling module mediates 
chemoresistance, about 45% of the GCB DLBCL subtype express high level of BCL-2 
as a consequence of the t(14;18) translocation. Therefore, apoptosis is blocked by 
BCL-2 independent of the status of NF-B pathway in GCB DLBCL. Unlike tumors 
characterized by a broad spectrum of detrimental biological properties directly linked 
to their constitutively active NF-B network, tumor types, such as GCB that do not 
rely on NF-B signaling as the driving oncogenic force but present with an 
NF-B-independent apoptotic block may use the prosenescent potential of NF-B 
signaling to execute TIS as an alternative, outcome-improving chemotherapeutic 
effector mechanism. 
 
Indeed, while NF-B mediates chemoresistance in ABC DLBCL, NF-B shows its 
beneficial function in GCB DLBCL. The GCB- reminiscent E-myc lymphomas were 
used to experimentally explore the contribution of enhanced NF-B activity to 
senescence induction after drug-inducible apoptosis was independently blocked by 
retroviral Bcl2 overexpression (a parallel or independent two-factor alternative of the 
same oncogenic network players). Lymphomas overexpressing a CARD11mutant, 
which results in persistent activation of the NF-B pathway, enter senescence at an 
early time, when lymphomas with normal NF-B activity were still largely negative for 
signs of TIS. This observation suggests that in tumors with apoptosis deficiency, 
instead of acting as an oncogenic factor, NF-B plays a positive role in the 
tumor-suppressive senescence process.  
 
ABC DLBCL has a worse survival after upfront chemotherapy and is characterized by 
constitutive activation of the antiapoptotic NF-B pathway, which mediates treatment 
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resistance. Our investigation in the E-myc transgenic lymphoma model confirmed 
that the NF-B/Bcl2 signaling module mediates chemoresistance in ABC-reminiscent 
lymphomas. Since apoptosis is blocked by NF-B/Bcl2 signaling in ABC-reminiscent 
lymphomas, one obvious question is whether they are able to make use of the 
constrictively activated NF-B pathway and enter senescence upon cancer therapy 
treatments.  Surprisingly, instead of being prone to senescence, ABC-reminiscent 
(NH) lymphomas displayed a senescence defect in comparison with 
GCB-reminiscent (NL) lymphomas. Although the detailed mechanism can not be 
addressed here, one possible explanation is that instead of hyperactive NF-B per se, 
the capability to be further activated is crucial for the induction of senescence. 
Possibly, the NF-B activity in ABC-reminiscent cells reached such a high level that 
the cancer therapeutic agents fail to further activate this pathway. 
 
Given the fact that senescence contributes to the outcome of cancer therapy, we 
asked whether hyperactive NF-B contributes to treatment outcome in human 
lymphoma patients. We used the genetic determinants of the TIS-prone 
scenario—GCB-reminiscent lymphomas with high Bcl2 expression were stratified by 
the level of NF-B activity—to interrogate a large GEP set derived from 233 DLBCL 
patients with known clinical outcome to therapy. Strikingly, we were able to confirm 
the mechanistic results from the murine lymphoma model in DLBCL-harboring 
patients. The ‘‘Bcl2 high/NF-B high’’ GCB DLBCL subgroup of patients presenting 
with a significantly prolonged survival after therapy underscores a hitherto unknown 
beneficial association of NF-B hyperactivation and treatment outcome in lymphoma 
patients. 
5.4 Context-dependency of NF-B in tumor 
development 
Nuclear translocation and subsequent DNA binding represent critical steps in the 
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NF-B pathway activation. However, the functional consequences of NF-B 
activation can differ dramatically depending on the nature of the inducer and the 
cellular context. NF-B can affect cancer development through the transcriptional 
activation of genes associated with cell proliferation, apoptosis suppression, 
angiogenesis, metastasis, tumor promotion and inflammation. Various mouse models 
of cancer in which IKK/NF-B activation has been blocked by genetic means have 
highlighted the key role of NF-B as a critical promoter of cancers. One of the most 
documented functions of NF-B is its ability to promote cell survival through induction 
of target genes whose products inhibit the apoptotic machinery in both normal and 
malignant cells. The biochemical and pathophysiologic roles of NF-B in 
carcinogenesis are confounded by its tumor suppression activity. In addition to a 
large volume of circumstantial evidence demonstrating constitutively active NF-B in 
many types of cancer, the underlying mechanism of the tumor-promoting effect of 
NF-B has been intensively explored. In contrast, how NF-B or its activation 
signaling contributes to tumor suppression remains a terra incognita. 
 
Our data highlight how oncogenic networks and interdependencies, wired up during 
tumor development, may regulate the actual functions and even opposing roles of 
NF-B in subsequent responses to therapy. NF-B mutations acquired during 
lymphoma development, as preferentially observed in the ABC subtype of DLBCL, 
account for the selective vulnerability of these lymphomas to NF-B inhibitors or 
shRNAs targeting components of the NF-B pathway (Davis et al. 2001; Ngo et al. 
2006). Since the anti-apoptotic bcl2 gene is a bona fide NF-B target, ABC DLBCL 
are genetically determined to depend on an NF-B/Bcl2 signaling module, while GCB 
DLBCL frequently present with bcl2 translocations that uncouple their anti-apoptotic 
activity from NF-B upstream control. While ABD DLBCL characterized by a broad 
spectrum of detrimental biological properties directly linked to the constitutively active 
NF-B network, GCB DLBCL present with an NF-B-independent apoptotic block and 
use the prosenescent potential of NF-B signaling to execute TIS as an alternative, 
outcome-improving chemotherapeutic effector mechanism. Our mouse model 
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findings obtained in Myc-driven lymphomas engineered to overexpress Bcl2 not only 
genetically approximate the human Myc/Bcl2 ‘‘double-hit’’ lymphomas frequently 
found in the GCB subtype of DLBCL, but also more advanced follicular lymphomas, 
which, in addition to their t(14;18) hallmark lesion, often acquire activating Myc 
lesions in the course of the disease, and, of note, also do not belong to 
NF-B-hyperactivated lymphoma entities (Aukema et al. 2011).  
5.5 Apoptosis or senescence: implications for 
cancer treatment 
In the validation and selection of targets for therapeutic intervention in cancer, the 
mutation or deregulation of a particular target or a pathway in human cancers may 
indicate of its importance in the malignancy process and the potential use of a drug 
that acts on that target or pathway. The IKK/NF-B signaling module is often altered 
in human cancers. Moreover, tumor cells appear to use NF-B to achieve resistance 
to anticancer drugs and irradiation. Therefore, inhibition of NF-B activation might be 
a promising option to improve the efficacy of conventional anti-cancer therapies.  
 
However, the relationship between NF-B and cancer is not simple and cannot be 
reduced to one grand theory. The complex role for NF-B in oncogenesis and the 
context dependency of NF-B signaling must be taken into account when designing 
NF-B–based therapies against cancer. Our study emphasizes the 
tumor-suppressive role of NF-B as a regulator of chemotherapy-induced 
senescence in vivo, particularly in tumors with an apoptosis deficiency. Therefore, 
inhibition of NF-B signaling might actually reduce chemo-efficacy instead of 
promoting cell death when apoptosis is defective. Our study underscores the 
importance of determining the context in which certain NF-B-mediated functions are 
preferentially executed. The mouse model and patient-derived data indicate that 
NF-B inhibitors should be rather applied to those cancers in which the 
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tumor-suppressive functions of NF-B are outweighed by verified NF-B oncogenic 
functions. In turn, tumors with an NF-B signaling predestined to promote 
senescence in response to DNA-damaging therapies, would rather not qualify as 
candidates for NF-B (co)-inhibition. In essence, our findings suggest that we should 
carefully select, or at least monitor, genetically defined patient subcohorts in which 
therapeutic interference with the NF-B pathway may or may not be of clinical benefit 
(Dunleavy et al. 2009; Ruan et al. 2011). 
5.6 E-myc transgenic mouse lymphomas—a model 
for human diffuse large B-cell lymphoma 
Human cancer is characterized by substantial heterogeneity, resulting from the 
acquisition of multiple somatic genetic and epigenetic alterations. Genetically 
engineered mouse models of human cancer are valuable tools for cancer research, in 
which genetic alterations can be directed without much complication. In this study, the 
E-myc transgenic lymphoma model was used to elucidate the function of NF-B in 
senescence and cancer treatment outcome. Myc is deregulated in various human 
cancers, such as lymphoma, breast cancer, and prostate cancer. Dysregualtion of the 
c-myc oncogene is a common genetic alteration in non-Hodgkin’s lymphoma. In 
Burkitt’s lymphoma, virtually every case involves chromosomal translocation of the 
myc locus to the IgH-J segment (Nesbit et al. 1999), resulting in overexpression of 
c-Myc in B cells. In addition to rearrangement, nonrandom somatic mutations within 
the myc coding region, which include those providing stabilization to the protein, have 
been observed. Burkitt-like (or atypical Burkitt) lymphoma and a fraction of diffuse 
large B-cell lymphoma (DLBCL) also feature Myc deregulation.  
 
The E-myc transgenic mouse is a valuable model for human aggressive B-cell 
non-Hodgkin’s lymphomas (B-NHL). Like most cancer models that are initiated by a 
defined genetic alteration, the development of lymphomas in the E-myc mouse 
107 
Discussion 
involves the acquisition of additional mutations (Mori et al. 2008), giving rise to some 
heterogeneity in the resulting tumors, thereby recapitulating a feature of naturally 
forming cancers. Suggested by the GEP classification of human diffuse large B-cell 
lymphoma, we classified the primary E-myc transgenic lymphomas into a 
GCB-reminiscent and an ABC-reminiscent group, allowing us to study the opposing 
role of NF-B in mouse model, to correlate findings with the human clinical data, and 
to reveal a clinically relevant group in which NF-B’s beneficial side is unveiled.  
 
Translocation of the Bcl2 gene, on encoded chromosome band 18q21.3, to the 
immunoglobulin (IG) heavy chain (IGH) gene as t(14;18)(q32;q21.3) results in 
consistent expression of the Bcl2 protein. Bcl2 translocation is detected in 70-95% of 
follicular lymphomas (Weiss et al. 1987) and 20% of diffuse large B cell lymphomas, 
whereby t(14;18) translocation are found virtually exclusively in the GCB subtype. 
Myc and Bcl2 co-activation is also seen in so-called “double-hit (DH) lymphomas". 
Double-hit lymphomas are defined by a chromosomal breakpoint affecting the 
myc/8q24 locus in combination with another recurrent breakpoint, mainly a 
t(14;18)(q32;q21) Bcl2-involving translocation. By using the Bcl-2 overexpressing 
Myc-driven B-cell lymphomas, we established a model for therapy-induced 
senescence. Technically, the Bcl-2 overexpression in myc lymphomas blocks 
apoptosis, thereby allowing senescence to occur throughout the tumor all population. 
Moreover, this model approximates the situation observed in patients with bcl2 
translocation and aggressive “double-hit” B-cell lymphomas with Myc and Bcl2 
translocations.  
5.7 Cross-species investigations—a novel approach 
to unveil clinically relevant patient subgroups 
Mouse models in which the various disease phenotypes resemble the spectrum of 
clinical manifestations in human provide valuable resources to understand molecular 
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pathogenesis and to test ways to prevent or treat the resulting diseases. Although the 
data in mouse models are valuable per se, it is important to translate information 
thereof back into the human condition. Cross-species investigations, which integrate 
the power of functional studies in mice and the combination of clinical-molecular data 
in patients, is a novel approach to unveil clinically relevant patient subgroups. 
 
In this thesis, we used mouse models to recapitulate defined genetic determinants of 
human tumor cohorts, followed by the genetic manipulation and subsequent 
functional exploration of murine surrogate tumors with the ultimate goal to use 
mouse-derived mechanistic information for a reassessment of the human data set to 
gain novel functional insights. Our data illustrate the power of cross-species 
investigations to redefine clinically relevant patient subcohorts. The cross-species 
investigation strategy was instrumental in unveiling a genetically defined tumor 
subset with a distinct NF-B-dependent responsiveness. The subgroup of human 
lymphoma patients who benefit from hyperactive NF-B would not have been 
identified without the cross-species investigation of primary Eμ-myc lymphomas.  
5.8 Open questions and outlook 
NF-B is viewed as a candidate target for cancer therapy because of the key role it 
plays in cancer development and progression. Our study demonstrates that settings 
exist in which NF-B stimulates tumor cells to enter senescence during 
chemotherapy and provides significant therapeutic implications. However, the 
experimental design in this study did not aim at explaining how precisely NF-B 
contributes to senescence. The detailed mechanism and signaling pathways involved 
still need to be further investigated. Our data suggested that ABC-reminiscent 
lymphomas have a senescence defect. On one hand, this explains the poor treatment 
outcome of ABC DLBCL from the perspective of senescence. On the other hand, this 
unveils the complexity of NF-B’s function in senescence. The detailed mechanisms 
require further investigation.  
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Our study sheds new light on the context-dependent roles of NF-B in oncogenesis 
and therapy. The opposing roles of NF-B in oncogenesis, promoting tumorigenesis 
on one hand and mediating therapy-induced senescence on the other, have 
significant therapeutic implications. First, these findings imply that the use of NF-B 
inhibitors in the clinic requires thorough assessment, since NF-B inhibition could 
interfere with the cytotoxicity of standard chemotherapy in combination therapies. 
Second, we observed that treatment-ralated activation of NF-B in mouse 
lymphomas with low NF-B activity enhances therapy-induced senescence; these 
results provide a rationale for the development of therapeutic strategies that enhance 
chemosensitivity by activating NF-B concomitantly with cytotoxic chemotherapy. 
Third, elucidating the precise mechanisms of NF-B in oncogenesis versus 
therapy-induced senescence could lead to the identification of crucial downstream 
components of NF-B that mediate chemosensitivity, with the eventual goal of 
developing strategies to boost senescence in tumors where NF-B’s oncogenic 
function dominates. The findings provide important new insights into the complexity of 
NF-B signaling in cancer cells. Future studies will exploit the development of specific, 
more effective anticancer therapies that utilize and/or target NF-B functionalities. 
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33B6.2 Abbrevations 
ABC Activated B-cell–like 
ADR Adriamycin 
ATM Ataxia telangiectasia mutated  
bp Base pair 
Bcl2 B cell lymphoma 2 
BSA Bovine serum albumin  
cDNA  Complementary DNA 
CTX Cyclophosphamide 
dH2O  Deionized water  
DAPI  4', 6-diamidino-2-phenylindole  
DDR DNA damage response  
DEPC Diethylpyrocarbonate 
DMEM Dulbecco´s modified Eagle medium 
dNTP 2’-deoxy nucleoside-5’-triphosphate 
DLBCL Diffuse large B-cell lymphoma 
DMSO Dimethylsulfoxid 
DNA Desoxyribonucleic acid 
DNase Deoxyribonuclease 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylendiamintetraacetat = Titriplex III 
FCS Fetal calf serum 
GCB Germinal-center B-cell-like 
GFP Green-fluorescent protein 
H3K9 Lysin 9 of Histone H3 
H3K9met3 Tri-methylated Lysine 9 of Histone H3 
HEPES N-2-hydroxyethylpiperazin-N'-2-ethanesulfonic acid 
IF Immunofluorescence 
IB Inhibitor of NF-B  
IKK IB Kinase  
IL-1  Interleukin-1 alpha 
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IL6 Interleukin 6 
IMDM Iscove's modified Dulbecco's medium 
IRES Internal ribosomal entry site 
kb Kilobase 
MEF Mouse embryonic fibroblasts  
mRNA Messenger ribonucleicacid 
MSCV Murine stem cell virus 
NF-B Nuclear Factor B  
NP-40 Nonidet P-40 
PAGE  Polyacrylamid-gel electrophoresis 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
pfu Plaque-forming unit 
PVDF Poly vinylidene difluoride 
Rb Retinoblastoma protein 
RNA Ribonucleic acid 
RNase Ribonuclease 
rpm Rotations per minute 
RT Room temperature 
SASP Senescence-associated secretory phenotype 
SA--Gal Senescence-associated -galactosidase 
SDS Natriumdodecylsulfat 
SR NF-B super repressor 
TAE Tris-acetate-EDTA 
TEMED N,N,N´,N´-Tetramethylethylendiamin 
TIS Therapy-induced senescence 
TNF Tumor necrosis factor-alpha 
Tris Tris (hydroxymethyl) aminomethane 
Triton X-100 Octylphenoldecaethylenglycolether 
Tween 20 Polyoxyethylensorbitanmonolaurat 
X-Gal 5-bromo-4-chloro-3-indolyl -D-galactoside 
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12B 0 Summary  
Utilizing the E-myc transgenic mouse lymphoma model, I showed in this thesis that 
therapy-induced senescence presents with and depends on active NF-B signaling, 
whereas NF-B simultaneously promotes resistance to apoptosis. By cross-species 
comparison of transcriptome data and clinical data from lymphoma patients, 
Bcl2-overexpressing germinal center B-cell-like DLBCL was identified as a clinically 
relevant subgroup with significantly superior outcome when NF-B is hyperactive. 
These results demonstrate the context-dependent role of NF-B signaling in cancer 
therapy. These findings suggest that we should carefully select, or at least monitor, 
genetically defined patient subcohorts in which therapeutic interference with the 
NF-B pathway may or may not be of clinical benefit. 
 
Resümee  
 
In der vorliegenden Arbeit konnte ich unter Verwendung des E-myc transgenen 
Mauslymphommodells zeigen, dass therapie-induzierte Seneszenz mit aktiviertem 
NF-B Signalweg verbunden ist und davon abhängt, während NF-B gleichzeitig 
Resistenz gegenüber Apoptose vermittelt. Durch einen „Cross-species”-Vergleich von 
Transkriptom- und Patientendaten wurden Bcl2-überexprimierende 
Keimzentrums-B-Zell-DLBCL als klinisch relevante Gruppe identifiziert, welche nach 
NF-B-Hyperaktivierung signifikant besser auf Therapie ansprach. Diese Ergebnisse 
zeigen eine kontext-spezifische Rolle des NF-B Signalwegs unter Chemotherapie. 
Die Daten suggerieren, dass wir genetisch definierte Patientengruppen, in denen 
therapeutische Interventionen im NF-B Signalweg einen klinischen 
Vor- beziehungsweise Nachteil darstellen könnten, genau beobachten und 
gegebenenfalls selektieren  sollten.  
 
